LIST OF US PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS GRANTED IN 2013
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included pharmaceutical
formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release; polysaccharides,
polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular or buccal
administration of medications and related subjects.
US Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Granted in 2013
Clck to enlarge and view details
 
US Patents Granted in 2013
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION GRANTED IN 2013



Patent No.: US8343533B2  Issued: 01/Jan/2013

Title: MANUFACTURE OF LOZENGE PRODUCT WITH RADIOFREQUENCY

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 12/887575   Filing Date: 22/Sep/2010

Abstract:

The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse the shape into said lozenge product.

Priority: US2009-245315P Applic. Date: 2009-09-24; US2009-255582P Applic. Date: 2009-10-28; US2010-314629P Applic. Date: 2010-03-17; US2010-358167P Applic. Date: 2010-06-24

Inventor: CHEN JEN-CHI [US]; SOWDEN HARRY S [US]; LUBER JOSEPH R [US]; KRIKSUNOV LEO B [US]; BUNICK FRANK J [US]; SZYMCZAK CHRISTOPHER E [US]; KOLL GREGORY E [US]


Patent No.: US8349796B2  Issued: 08/Jan/2013

Title: Methods for treatment of distraction osteogenesis using PDGF

Applicant/Assignee: BIOMIMETIC THERAPEUTICS, INC, BIOMIMETIC THERAPEUTICS INC

Application No.: 13/048795   Filing Date: 15/Mar/2011

Abstract:

The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.

Priority: US2009-368242 Applic. Date: 2009-02-09; US2008-026934P Applic. Date: 2008-02-07

Inventor: LYNCH SAMUEL E [US]; HART CHARLES E [US]; EHRLICH MICHAEL G [US]; MOORE DOUGLAS C [US]


Patent No.: US8354119B2  Issued: 15/Jan/2013

Title: Resorbable extracellular matrix containing collagen I and collagen II for reconstruction of cartilage

Applicant/Assignee: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIE

Application No.: 10/299008   Filing Date: 19/Nov/2002

Abstract:

A resorbable extracelluar matrix for reconstruction of cartilage tissue includes a mixture of collagen I and collagen II in a respective ratio of from about 1:19 to 19:1. The matrix can be utilized as a scaffold implant for vertebral or meniscal cartilage regeneration.

Priority: US2001-331618P Applic. Date: 2001-11-20

Inventor: GEISTLICH PETER [CH]; SCHLOESSER LOTHAR [DE]


Patent No.: US8354123B2  Issued: 15/Jan/2013

Title: NON-ADHESIVE ELASTIC GELATIN MATRICES

Applicant/Assignee: COVALON TECHNOLOGIES INC

Application No.: 13/166433   Filing Date: 22/Jun/2011

Abstract:

The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.

Priority: US2005-664184 Applic. Date: 2005-06-15; WO2005CA00925 Applic. Date: 2005-06-15; US2004-614414P Applic. Date: 2004-09-30

Inventor: DITIZIO VALERIO [CA]; DICOSMO FRANK [CA]; XIAO YUEHUA [CA]


Patent No.: US8357357B2  Issued: 22/Jan/2013

Title: 3.2.1-bicyclo-octene and -octane compounds

Applicant/Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC

Application No.: 12/901077   Filing Date: 08/Oct/2010

Abstract:

The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octene and -octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of hydrogen, acetate, carbonate monomethyl ester, and allyloxy

and wherein the broken line represents a single or double bond.

Priority:

Inventor: CLOSSON ADAM P [US]; AMORELLI BENJAMIN [US]; O'KEEFE NICOLE [US]


Patent No.: US8357358B2  Issued: 22/Jan/2013

Title: 3.2.1-bicyclo-octane compounds

Applicant/Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC

Application No.: 12/901097   Filing Date: 08/Oct/2010

Abstract:

The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of carbonyl and [1,3]dioxolane

R' is selected from the group consisting of hydrogen and allyl

or R and R' taken together represent

Priority:

Inventor: CLOSSON ADAM P [US]; AMORELLI BENJAMIN [US]; O'KEEFE NICOLE [US]


Patent No.: US8357383B2  Issued: 22/Jan/2013

Title: PERSONAL CARE IMPLEMENT CONTAINING A STABLE REACTIVE SKIN CARE AND CLEANSING COMPOSITION

Applicant/Assignee: UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC, CONOPCO, INC

Application No.: 12/893096   Filing Date: 29/Sep/2010

Abstract:

Skin care or cleansing implements are described containing a liquid, semi-solid or solid cleansing or skin treatment composition that is releasably associated with the implement. The composition is substantially nonaqueous and has a continuous and a discontinuous phase. Components of the discontinuous phase can react with each other or with water when water is blended with the nonaqueous cleansing or skin treatment composition during consumer use. Methods for treating the skin with the inventive implements are also described.

Priority: US2003-742984 Applic. Date: 2003-12-22

Inventor: SPADINI ALESSANDRO LUIGI [US]; KATZ MELISSA IVA [US]; WILLIAMS DAVID ROBERT [US]; SICILIANO MARCINA [US]; GRISSETT GREGORY AARON [US]; HILLMAN EVAN [US]; PULEO ANDRE [US]; HURLEY MEGAN KATHLEEN [US]


Patent No.: US8357388B2  Issued: 22/Jan/2013

Title: DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/716383   Filing Date: 03/Mar/2010

Abstract:

The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.

Priority: US2007-734618 Applic. Date: 2007-04-12; US2006-403733 Applic. Date: 2006-04-13

Inventor: MCKAY WILLIAM F [US]


Patent No.: US8357399B2  Issued: 22/Jan/2013

Title: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 13/544333   Filing Date: 09/Jul/2012

Abstract:

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.

Priority: US2010-909614 Applic. Date: 2010-10-21; US2003-689866 Applic. Date: 2003-10-21; US2001-781081 Applic. Date: 2001-02-08; US2000-181369P Applic. Date: 2000-02-08

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; HADDOX J DAVID [US]


Patent No.: US8357645B2  Issued: 22/Jan/2013

Title: Semi-Rigid Gel Cleansing Article and Uses Thereof

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE, THE CLOROX COMPANY

Application No.: 12/055667   Filing Date: 26/Mar/2008

Abstract:

The present invention relates to semi-rigid gels, methods of manufacture and uses thereof.

Priority: US2007-920696P Applic. Date: 2007-03-28

Inventor: GLENN GREGORY M [US]; STEPHENSON SERENA [US]; MANALO NIKITA R [US]; LESTAGE DAVID [US]; PRIVITERA MARC [US]


Patent No.: US8361499B2  Issued: 29/Jan/2013

Title: CONTROLLED RELEASE HYDROCODONE FORMULATIONS

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 13/535996   Filing Date: 28/Jun/2012

Abstract:

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Priority: US2010-914054 Applic. Date: 2010-10-28; US2009-378586 Applic. Date: 2009-02-17; US2003-660349 Applic. Date: 2003-09-11; US2001-016651 Applic. Date: 2001-10-30; US2000-244424P Applic. Date: 2000-10-30

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN K [US]; TONELLI ALFRED P [US]


Patent No.: US8361501B2  Issued: 29/Jan/2013

Title: Non-adhesive elastic gelatin matrices

Applicant/Assignee: COVALON TECHNOLOGIES, INC

Application No.: 11/152367   Filing Date: 15/Jun/2005

Abstract:

The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.

Priority: US2004-614414P Applic. Date: 2004-09-30

Inventor: DITIZIO VALERIO [CA]; DICOSMO FRANK [CA]; XIAO YUEHUA [CA]


Patent No.: US8361502B2  Issued: 29/Jan/2013

Title: Compositions and methods for the expansion and differentiation of stem cells

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 11/975492   Filing Date: 18/Oct/2007

Abstract:

The instant invention provides methods and compositions for the expansion and differentiation of stem cells.

Priority: US2006-852598P Applic. Date: 2006-10-18

Inventor: MAO HAI-QUAN [US]; LEONG KAM W [US]; CHUA KIAN-NGIAP [SG]; RAMAKRISHNA SEERAM [SG]


Patent No.: US8361503B2  Issued: 29/Jan/2013

Title: Extracellular Matrix-Derived Gels and Related Methods

Applicant/Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: 12/040140   Filing Date: 29/Feb/2008

Abstract:

Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

Priority: US2007-892699P Applic. Date: 2007-03-02

Inventor: BADYLAK STEPHEN F [US]; FREYTES DONALD O [US]


Patent No.: US8362088B2  Issued: 29/Jan/2013

Title: METHOD AND ARTICLE OF MANUFACTURE FOR ENCAPSULATING A HOMEOPATHIC INGREDIENT WITH A SECOND INGREDIENT

Applicant/Assignee:

Application No.: 11/956019   Filing Date: 13/Dec/2007

Abstract:

An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Priority: US2006-874732P Applic. Date: 2006-12-14

Inventor: WARNOCK W MATTHEW [US]; HINZE SHANE [US]


Patent No.: US8367082B2  Issued: 05/Feb/2013

Title: Microgel and external compositions containing the same

Applicant/Assignee: SHISEIDO CO., LTD, SHISEIDO COMPANY, LTD

Application No.: 12/082130   Filing Date: 09/Apr/2008

Abstract:

The present invention provides a microgel having a mean particle size of 0.1-1,000 [mu]m, the microgel being produced from a gel which is formed by use of a hydrophilic compound capable of forming a gel. An external composition containing the microgel provides an excellent sensation during use

i.e., the composition provides neither sticky sensation during use nor frictional sensation. Furthermore, even when a large amount of a pharmaceutical ingredient, such as a whitening ingredient, or a salt is incorporated into the composition, the viscosity of the composition is not lowered, and the composition exhibits excellent viscosity increasing property. In addition, the composition exhibits long-term stability, without inviting separation of water.

Priority: JP20000002610 Applic. Date: 2000-01-11; JP20000002611 Applic. Date: 2000-01-11; JP20000094307 Applic. Date: 2000-03-30; JP20000094308 Applic. Date: 2000-03-30; US2001-936317 Applic. Date: 2001-11-06

Inventor: MIYAZAWA KAZUYUKI [JP]; KANEDA ISAMU [JP]; YANAKI TOSHIO [JP]; NAKAMURA TADASHI [JP]; OCHIAI MASATOSHI [JP]; KAWASOE TOMOYUKI [JP]


Patent No.: US8367118B2  Issued: 05/Feb/2013

Title: SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 13/560731   Filing Date: 27/Jul/2012

Abstract:

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

Priority: US2003-458840 Applic. Date: 2003-06-09; US2001-770562 Applic. Date: 2001-01-26; US1998-131019 Applic. Date: 1998-08-07; US1997-055221P Applic. Date: 1997-08-11

Inventor: CURATOLO WILLIAM J [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]


Patent No.: US8372424B2  Issued: 12/Feb/2013

Title: STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES

Applicant/Assignee: INTARCIA THERAPEUTICS, INC

Application No.: 13/596971   Filing Date: 28/Aug/2012

Abstract:

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 110-7 reciprocal second.

Priority: US201213454063 Applic. Date: 2012-04-23; US201113043288 Applic. Date: 2011-03-08; US2008-075435 Applic. Date: 2008-03-11; US2000-627531 Applic. Date: 2000-07-28; US2000-497422 Applic. Date: 2000-02-03; US1999-119170P Applic. Date: 1999-02-08

Inventor: BERRY STEPHEN A [US]; FEREIRA PAMELA J [US]; DEHNAD HOUDIN [US]; MUCHNIK ANNA [US]


Patent No.: US8372433B2  Issued: 12/Feb/2013

Title: SUBSTRATE FOR CULTURE OF CARDIOVASCULAR TISSUE

Applicant/Assignee: GUNZE LIMITED

Application No.: 12/523124   Filing Date: 18/Jan/2008

Abstract:

The scaffold for culturing a cardiovascular tissue of the present invention is a scaffold for culturing a cardiovascular tissue, which is tubular, and comprises a foamed polymer comprising a bioabsorbable material reinforced with a reinforcing material comprising a bioabsorbable material, the foamed polymer comprising lactide (D, L, DL isomer)-[epsilon]-caprolactone copolymer containing lactide (D, L, DL isomer) in a content of 50 to 54 mole % and [epsilon]-caprolactone in a content of 50 to 46 mole %, and the reinforcing material being covered with the foamed polymer.

Priority: JP20070009469 Applic. Date: 2007-01-18; WO2008JP50609 Applic. Date: 2008-01-18

Inventor: SHINOKA TOSHIHARU [JP]; MATSUMURA GOKI [JP]; IKADA YOSHITO [JP]; MATSUDA SHOJIRO [JP]; SAKAMOTO YUKI [JP]; TAIRA TSUGUYOSHI [JP]


Patent No.: US8372646B1  Issued: 12/Feb/2013

Title: Terpene media compositions for eluting compounds from matrices and methods for making and using them

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 12/961218   Filing Date: 06/Dec/2010

Abstract:

Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended polymer matrix. Such methods and materials can be used for example to assess and control the manufacturing process variability of drug eluting implantable devices such as cardiac leads.

Priority: US2009-643652 Applic. Date: 2009-12-21

Inventor: CHATTARAJ SARNATH [US]; GULATI POONAM S [US]; LEVIN EUGENE [US]


Patent No.: US8377461B2  Issued: 19/Feb/2013

Title: Multifunctional medical articles

Applicant/Assignee: SURMODICS, INC

Application No.: 11/295836   Filing Date: 06/Dec/2005

Abstract:

The invention provides medical articles that include more than one biocompatibility-promoting function. In one aspect, the invention provides a medical articles that include a polymeric matrix including more than one biocompatible agent, wherein each biocompatible agent is provided at a distinct portion of the medical article surface. Methods of making medical articles, as well as methods of using the same, are also described.

Priority: US2004-633841P Applic. Date: 2004-12-06

Inventor: CHINN JOSEPH A [US]; STUCKE SEAN M [US]; CHUDZIK STEPHEN J [US]


Patent No.: US8383153B2  Issued: 26/Feb/2013

Title: POLY(AMIDOAMINE) OLIGOMER HYDROGEL FOR DRUG DELIVERY AND DRUG CARRIER USING THE SAME

Applicant/Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION, SUNGYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION

Application No.: 12/938852   Filing Date: 03/Nov/2010

Abstract:

Disclosed is a temperature- and pH-sensitive hydrogel composed of a poly(amidoamine) oligomer only. The hydrogel is prepared in a simple manner and is readily released from the body. Further disclosed are a method for preparing the hydrogel and a drug carrier using the hydrogel.

Priority: KR20100019215 Applic. Date: 2010-03-03

Inventor: LEE DOO SUNG [KR]; KIM BONG SUP [KR]; NGUYEN MINH KHANH [KR]


Patent No.: US8383158B2  Issued: 26/Feb/2013

Title: Methods and compositions to treat myocardial conditions

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 10/414602   Filing Date: 15/Apr/2003

Abstract:

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include, but are not, limited to pro-fibroblastic and angiogenic agents.

Priority: US2003-414767 Applic. Date: 2003-04-15

Inventor: MICHAL EUGENE T [US]; MANDRUSOV EVGENIA [US]; CLAUDE CHARLES D [US]; DING NI [US]; SIMHAMBHATLA MURTHY [US]; HOSSAINY SYED FAIYEZ AHMED [US]; SRIDHARAN SRINIVASAN [US]; CONSIGNY PAUL [US]


Patent No.: US8383415B2  Issued: 26/Feb/2013

Title: Hydrogel composition to enhance fluorescence

Applicant/Assignee: DSO NATIONAL LABORATORIES

Application No.: 12/083593   Filing Date: 28/Nov/2008

Abstract:

A composition comprising a hydrogel particle and a fluorophore

wherein said composition produces an enhanced fluorescent signal when excited by an energy source capable of exciting the fluorophore.

Priority: WO2005SG00353 Applic. Date: 2005-10-13

Inventor: AYI TECK CHOON [SG]; TONG MEI-MEI JILL [SG]; LEE VEE SIN PETER [SG]


Patent No.: US8383688B2  Issued: 26/Feb/2013

Title: Products with water clusters

Applicant/Assignee: D & Y LABORATORIES

Application No.: 12/592877   Filing Date: 03/Dec/2009

Abstract:

A product has solid stable water clusters including a plurality of water molecules connected with one another by electrical dipole interaction via internal electric field of ions and having a permanent electric dipole moment with an electrical field surrounding the solid stable water clusters.

Priority: US2008-200821P Applic. Date: 2008-12-04; US2008-200823P Applic. Date: 2008-12-04; US2008-200824P Applic. Date: 2008-12-04; US2008-200825P Applic. Date: 2008-12-04; US2009-210064P Applic. Date: 2009-03-14; US2009-210065P Applic. Date: 2009-03-14; US2009-217604P Applic. Date: 2009-06-02; US2009-217605P Applic. Date: 2009-06-02; US2009-217680P Applic. Date: 2009-06-03

Inventor: LO SHUI YIN [US]; GANN DAVID [US]; XU GENG [US]


Patent No.: US8383689B2  Issued: 26/Feb/2013

Title: Skin cosmetics comprising cocoon-shaped polymer fine particles

Applicant/Assignee: GANZ CHEMICAL CO., LTD, AICA KOGYO CO., LTD

Application No.: 12/453112   Filing Date: 29/Apr/2009

Abstract:

The present skin cosmetics comprising cocoon-shaped polymer fine particles having an average particle size of 1 to 8 [mu]m and cosmetic vehicles show an effect of making fine wrinkles on the skin unnoticeable, letting the skin appear smoother and fairer.

Priority:

Inventor: TANAKA KOICHIRO [JP]; TANAKA SHUNSAKU [JP]; NEGAYAMA SADAO [JP]; ISHII NAOMI [JP]


Patent No.: US8388994B1  Issued: 05/Mar/2013

Title: Fibrous non-woven polymeric material

Applicant/Assignee:

Application No.: 12/481189   Filing Date: 09/Jun/2009

Abstract:

The present invention relates to biocompatible non-woven fibrous materials having a nano-micro topography and methods for producing such materials. The materials may be used to cover implantable medical devices and to fabricate a three-dimensional drug-eluting fibrous matrix featuring accurate spatial positioning of the drug particles within the matrix.

Priority: US2008-060106P Applic. Date: 2008-06-09

Inventor: SCHEER INGO [US]; BEAUMONT CLAUDIA [US]


Patent No.: US8388997B2  Issued: 05/Mar/2013

Title: METHOD OF PREPARING AN UNSATURATED FATTY ACID DRY CONCENTRATE

Applicant/Assignee: VIS-VITALIS LIZENZ-UND HANDELS GMBH

Application No.: 13/243988   Filing Date: 23/Sep/2011

Abstract:

There is provided a method of preparing an unsaturated fatty acid dry concentrate, wherein a substance comprising at least one unsaturated fatty acid is applied on a biologically inert matrix having a large surface area and is subsequently dried, as well as a composition comprising at least one unsaturated fatty acid and foods, beverages, drugs comprising this composition.

Priority: AT20000001063 Applic. Date: 2000-06-20; US2003-312077 Applic. Date: 2003-04-14; WO2001AT00197 Applic. Date: 2001-06-19

Inventor: FUCHS NORBERT [AT]; KOESSLER PETER [AT]


Patent No.: US8389009B2  Issued: 05/Mar/2013

Title: Spatial control of signal transduction

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 11/412450   Filing Date: 27/Apr/2006

Abstract:

Substrates and matrices for spatial control of signal transduction by a biologically active, soluble molecule that transduces a signal to a cell responsive to the molecule are disclosed.

Priority: US2005-675225P Applic. Date: 2005-04-27

Inventor: MURPHY WILLIAM LEO [US]; HUDALLA GREGORY ALLAN [US]


Patent No.: US8399015B2  Issued: 19/Mar/2013

Title: Solid Pharmaceutical Dosage Form

Applicant/Assignee: ABBOTT LABORATORIES, ABBVIE INC

Application No.: 13/240119   Filing Date: 22/Sep/2011

Abstract:

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 DEG C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Priority: US2004-925442 Applic. Date: 2004-08-25; US2003-498412P Applic. Date: 2003-08-28

Inventor: ROSENBERG JOERG [DE]; REINHOLD ULRICH [DE]; LIEPOLD BERND [DE]; BERNDL GUNTHER [DE]; BREITENBACH JOERG [DE]; ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Patent No.: US8399018B2  Issued: 19/Mar/2013

Title: CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS

Applicant/Assignee: OTONOMY, INC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/506664   Filing Date: 21/Jul/2009

Abstract:

Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.

Priority: US2008-082450P Applic. Date: 2008-07-21; US2008-094384P Applic. Date: 2008-09-04; US2008-101112P Applic. Date: 2008-09-29; US2008-140033P Applic. Date: 2008-12-22; US2008-088275P Applic. Date: 2008-08-12

Inventor: LICHTER JAY [US]; VOLLRATH BENEDIKT [US]; DURON SERGIO G [US]; LEBEL CARL [US]; PIU FABRICE [US]; YE QIANG [US]; DELLAMARY LUIS A [US]; TRAMMEL ANDREW M [US]; SCAIFE MICHAEL CHRISTOPHER [US]; HARRIS JEFFREY P [US]


Patent No.: US8399019B2  Issued: 19/Mar/2013

Title: ORAL DELIVERY VEHICLE AND MATERIAL

Applicant/Assignee: FOODSOURCE LURES CORPORATION

Application No.: 13/457604   Filing Date: 27/Apr/2012

Abstract:

Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take the form of a pouch or capsule. Alternatively, a medicament or other substance to be orally delivered can be coated with the composition. In another alternative, the medicament or other substance to be orally delivered can be dispersed within a matrix of the composition. The compositions for the oral delivery vehicle are also suitable for use as an animal food or treat or use as a hunting bait or lure.

Priority: US2008-909848 Applic. Date: 2008-05-13; WO2006US11428 Applic. Date: 2006-03-28; US2005-665703P Applic. Date: 2005-03-28

Inventor: ROGERS ED [US]; GILBERT ROY W [US]


Patent No.: US8404255B2  Issued: 26/Mar/2013

Title: SYSTEM AND METHOD FOR TRANSDERMAL DRUG DELIVERY

Applicant/Assignee:

Application No.: 12/334379   Filing Date: 12/Dec/2008

Abstract:

In the preferred embodiment, the invention is a system for creating micropores in the skin for transdermal drug delivery through the micropores and includes: a chemical that dissolves or breaks down superficial layers of skin

a chemical delivery element that holds and delivers controlled volumes of the chemical to skin, creating micropores

and a base that is able to temporarily couple to skin, contains the chemical delivery elements, and may activate the chemical delivery elements to administer the chemical to skin. In the preferred embodiment, the invention is a method for delivering drugs transdermally that includes providing a carrier containing a chemical delivery element with a chemical to break down superficial layers of skin

placing the carrier into contact with skin

activating the chemical delivery element

allowing the chemical to break down superficial layers of skin and creating micropores

and providing a drug to be delivered transdermally through the micropores.

Priority: US2008-084585P Applic. Date: 2008-07-29

Inventor: GIBSON MATT [US]; KOZAI TAKASHI YOSHIDA [US]; PURCELL ERIN [US]


Patent No.: US8404277B2  Issued: 26/Mar/2013

Title: MATRIX-TYPE TRANSDERMAL DRUG DELIVERY SYSTEM AND PREPARATION METHOD THEREOF

Applicant/Assignee: SAMYANG CORPORATION, SAMYANG BIOPHARMACEUTICALS CORPORATION

Application No.: 12/602256   Filing Date: 05/Jun/2008

Abstract:

A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer

a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer

and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation.

Priority: KR20070056299 Applic. Date: 2007-06-08; WO2008KR03166 Applic. Date: 2008-06-05

Inventor: SONG JIN-DEOK [KR]; KIM DONG-WON [KR]


Patent No.: US8404751B2  Issued: 26/Mar/2013

Title: Subunguicide, and Method for Treating Onychomycosis

Applicant/Assignee: HALLUX, INC

Application No.: 12/606324   Filing Date: 27/Oct/2009

Abstract:

Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly using a solid, semi-solid, or flowable carrier. The carrier can be in the form of a semi-solid into which the user digs and scrapes the nail, a solid carrier can be inserted directly under the nail in contact with the nail bed, or a flowable composition can be injected in contact with the nail bed.

Priority: US2006-523508 Applic. Date: 2006-09-19; US2003-671307 Applic. Date: 2003-09-25; US2002-414012P Applic. Date: 2002-09-27

Inventor: BIRNBAUM JAY E [US]; JOHNSON KEITH A [US]


Patent No.: US8409594B2  Issued: 02/Apr/2013

Title: Solid Oil-In-Water Emulsion

Applicant/Assignee: OTSUKA PHARMACEUTICAL CO., LTD

Application No.: 11/722965   Filing Date: 27/Dec/2005

Abstract:

The present invention aims to provide solid compositions comprising an oil-in-water emulsion that have sufficient hardness and good feel when used, and can sufficiently exhibit the physiological functions of an electrolyte. A solid composition is obtained by preparing an oil-in-water emulsion by combining a solid oil (A), a liquid oil (B), a surfactant (C), a polyhydric alcohol (D), an electrolyte (E), and water (F).

Priority: JP20040381162 Applic. Date: 2004-12-28; WO2005JP23865 Applic. Date: 2005-12-27

Inventor: SHINOHARA SHIGEO [JP]; HARANO FUMIKI [JP]; TSUJIMOTO SHINJI [JP]; SAEKI ISAMU [JP]


Patent No.: US8409610B2  Issued: 02/Apr/2013

Title: Wound care device

Applicant/Assignee: COLOPLAST A/S

Application No.: 13/230479   Filing Date: 12/Sep/2011

Abstract:

A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.

Priority: DK20030000920 Applic. Date: 2003-06-19; US2005-560181 Applic. Date: 2005-12-09; WO2004DK00427 Applic. Date: 2004-06-18

Inventor: FRIIS GITTE JUEL [DK]; LARSEN TRUELS STERM [DK]


Patent No.: US8409613B2  Issued: 02/Apr/2013

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee: DEPOMED, INC

Application No.: 13/396441   Filing Date: 14/Feb/2012

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2010-749101 Applic. Date: 2010-03-29; US2008-239591 Applic. Date: 2008-09-26; US2002-280309 Applic. Date: 2002-10-25; US2001-335248P Applic. Date: 2001-10-25

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Patent No.: US8409616B2  Issued: 02/Apr/2013

Title: Opioid abuse deterrent compositions and methods of making same

Applicant/Assignee: ACURA PHARMACEUTICALS, INC

Application No.: 13/327252   Filing Date: 15/Dec/2011

Abstract:

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Priority: US2009-383906 Applic. Date: 2009-03-30; US2007-716122 Applic. Date: 2007-03-09; US2003-723654 Applic. Date: 2003-11-26

Inventor: KUMAR VIJAI [US]; DIXON DAVID [US]; TEWARI DIVYA [US]; WADGAONKAR DILIP B [US]


Patent No.: US8409625B2  Issued: 02/Apr/2013

Title: Conditioned Decellularized Native Tissues for Tissue Restoration

Applicant/Assignee: ACELL, INC

Application No.: 12/351757   Filing Date: 09/Jan/2009

Abstract:

The invention provides a composition conditioned for the remodeling, restoration, repair, or replacement of tissue within a host. The composition is conditioned by culturing cells on the matrix and/or by exposing the cultured cells or matrix to one or more stressors.

Priority: US2004-876299 Applic. Date: 2004-06-24; US2003-482480P Applic. Date: 2003-06-25; US2004-538385P Applic. Date: 2004-01-21

Inventor: BADYLAK STEPHEN F [US]


Patent No.: US8414906B2  Issued: 09/Apr/2013

Title: Additives and products including oligoesters

Applicant/Assignee: CRODA, INC

Application No.: 12/586442   Filing Date: 22/Sep/2009

Abstract:

The present invention relates to oligoesters and their use for the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can impart conditioning, long substantivity and/or UV protection. Individual oligoesters and oligoester mixtures are described.

Priority: US2003-356208 Applic. Date: 2003-01-31; US2002-353669P Applic. Date: 2002-01-31; US2002-353477P Applic. Date: 2002-01-31; US2002-353540P Applic. Date: 2002-02-01

Inventor: PEREIRA ABEL G [US]; BARINOVA HELENA S [US]; WESTERGOM CHRISTOPHER [US]


Patent No.: US8414919B2  Issued: 09/Apr/2013

Title: Sustained Drug Release Composition

Applicant/Assignee: ANGELINI LABOPHARM, LLC

Application No.: 12/905567   Filing Date: 15/Oct/2010

Abstract:

The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.

Priority: US2006-519189 Applic. Date: 2006-09-11; US2005-715162P Applic. Date: 2005-09-09

Inventor: GERVAIS SONIA [CA]; SMITH DAMON [CA]; CONTAMIN PAULINE [FR]; OUZEROUROU RACHID [CA]; MA MY LINH [CA]


Patent No.: US8414923B2  Issued: 09/Apr/2013

Title: IMMOBILIZATION OF BIOACTIVE MOLECULES WITHIN A POLYMERIC SUBSTRATE

Applicant/Assignee:

Application No.: 12/677865   Filing Date: 12/Sep/2008

Abstract:

A method for the immobilization of bioactive molecules within a polymer substrate to be employed as an oral drug delivery system is provided. A water insoluble carrier matrix can be provided that is water swellable, and biologically active agents can be incorporated. The matrix can be a macromolecular network synthesized by gamma radiation at temperatures between -78 degrees Celsius to a boiling point of a component elected for polymerization.

Priority: AR2007P104071 Applic. Date: 2007-09-13; WO2008IB02368 Applic. Date: 2008-09-12

Inventor: SMOLKO EDUARDO ESTEBAN [AR]; LOMBARDO EDUARDO ANTONIO [AR]; LOMBARDO FABIO MARTIN [AR]; LOMBARDO JORGE HECTOR [IT]


Patent No.: US8414924B2  Issued: 09/Apr/2013

Title: PREPARATION FOR TREATING HEART DISEASE USED IN CELL THERAPY

Applicant/Assignee: KYOTO UNIVERSITY

Application No.: 12/681940   Filing Date: 09/Oct/2008

Abstract:

An object of the present invention is to establish a cell transplantation method which can markedly improve the survival of grafted pluripotent stem cells and the efficiency of cardiomyocyte regeneration in cell therapy using pluripotent stem cells derived from heart tissue and can treat heart disease further effectively. Specifically, according to the present invention, enhancement in the survival of grafted pluripotent stem cells and significant improvement in the efficiency of cardiomyocyte regeneration are achieved by using, in combination, pluripotent stem cells derived from heart tissue and a hydrogel containing a basic fibroblast growth factor (bFGF) in cell therapy for heart disease.

Priority: JP20070265008 Applic. Date: 2007-10-10; WO2008JP68809 Applic. Date: 2008-10-09

Inventor: OH HIDEMASA [JP]; TAKEHARA NAOFUMI [JP]; MATSUBARA HIROAKI [JP]; TABATA YASUHIKO [JP]


Patent No.: US8415389B2  Issued: 09/Apr/2013

Title: POLYPHENOL-BASED COMPOSITION, AND METHODS AND SYSTEMS FOR ITS PREPARATION

Applicant/Assignee:

Application No.: 12/022391   Filing Date: 30/Jan/2008

Abstract:

A system for preparing a polyphenol containing formulation includes a first component which is a polyphenol and a second component which is the solvent system for the polyphenol. The solvent system includes water and a surfactant which is an ester of a dicarboxylic acid. The components are maintained separately from one another and are mixed prior to use. Specific compositions prepared through the use of the system include polyphenols and a solvent system based upon diaryl sulfosuccinate salts, water and optional glycols together with ancillary ingredients such as buffers, preservatives, coloring agents, fragrances, and thickeners.

Priority: US2007-887399P Applic. Date: 2007-01-31

Inventor: KULESZA JOHN E [US]


Patent No.: US8420117B2  Issued: 16/Apr/2013

Title: Patch Formulation For External Use

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: 12/831190   Filing Date: 06/Jul/2010

Abstract:

A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.

Priority: JP19990212921 Applic. Date: 1999-07-27; US2004-754592 Applic. Date: 2004-01-12; US2002-031747 Applic. Date: 2002-01-24; WO2000JP04945 Applic. Date: 2000-07-25

Inventor: CHONO HIDEHARU [JP]; YAMAGUCHI TOSHIRO [JP]; KURITA HISAKAZU [JP]; TATEISHI TETSURO [JP]; HIGO NARUHITO [JP]


Patent No.: US8420121B2  Issued: 16/Apr/2013

Title: DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 12/845126   Filing Date: 28/Jul/2010

Abstract:

Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO2 in their environment, thus regulating release of an entrapped drug.

Priority: US2009-229287P Applic. Date: 2009-07-29

Inventor: THAYUMANAVAN SANKARAN [US]


Patent No.: US8425937B2  Issued: 23/Apr/2013

Title: Pharmaceutical Compositions for Glucocorticoid Replacement Therapy

Applicant/Assignee: DUOCORT AB, DUOCORT PHARMA AB

Application No.: 11/587514   Filing Date: 13/Sep/2007

Abstract:

The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents.

The invention also relates to a kit comprising a first and a second component, the first component designed to release one or more glucocorticoids substantially immediately and the second component is designed to release one or more glucocorticoids over an extended period of time of at least 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. In another aspect the invention relates to the use of a first and a second amount of one or more glucocorticoids for the preparation of a pharmaceutical composition or kit for the treatment of a glucocorticoid deficiency disorder.

Priority: SE20040001031 Applic. Date: 2004-04-22; US2004-564205P Applic. Date: 2004-04-22; WO2005EP04400 Applic. Date: 2005-04-21

Inventor: SKRTIC STANKO [SE]; JOHNSSON JOERGEN [SE]; LENNERNAES HANS [SE]; HEDNER THOMAS [SE]; JOHANNSSON GUDMUNDUR [SE]


Patent No.: US8426476B2  Issued: 23/Apr/2013

Title: BIOBENEFICIAL COATING COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/874898   Filing Date: 02/Sep/2010

Abstract:

A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.

Priority: US2003-723043 Applic. Date: 2003-11-26

Inventor: PACETTI STEPHEN D [US]


Patent No.: US8431158B2  Issued: 30/Apr/2013

Title: COMPOSITIONS COMPRISING FIBROUS POLYPEPTIDES AND POLYSACCHARIDES

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM LTD, COLLPLANT LTD

Application No.: 12/744703   Filing Date: 26/Nov/2008

Abstract:

Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.

Priority: US2007-996581P Applic. Date: 2007-11-26; US2008-071968P Applic. Date: 2008-05-28; WO2008IL01542 Applic. Date: 2008-11-26

Inventor: SHOSEYOV ODED [IL]; LAPIDOT SHAUL [IL]; MEIROVITCH SIGAL [IL]; SIEGEL DANIEL L [IL]


Patent No.: US8431587B2  Issued: 30/Apr/2013

Title: METHOD FOR THE TREATMENT OF CANCER

Applicant/Assignee: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK

Application No.: 12/836626   Filing Date: 15/Jul/2010

Abstract:

The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.

Priority: US2009-225949P Applic. Date: 2009-07-16

Inventor: MCKENNA SHARON [IE]; O'SULLIVAN GERALD C [IE]; O'DONOVAN TRACEY [IE]


Patent No.: US8435496B2  Issued: 07/May/2013

Title: NANOPARTICLE CLUSTERS AND METHODS FOR FORMING SAME

Applicant/Assignee: DUBLIN CITY UNIVERSITY

Application No.: 12/519132   Filing Date: 12/Dec/2007

Abstract:

A method for providing nanoparticle clusters of controlled dimensions is described. The method involves an activation of individual nanoparticles and the subsequent interaction between activated particles to form a cluster.

Priority: EP20060125979 Applic. Date: 2006-12-12; WO2007EP63815 Applic. Date: 2007-12-12

Inventor: BROUGHAM DERMOT [IE]; GHOSH SWAPANKUMAR [IN]


Patent No.: US8435565B2  Issued: 07/May/2013

Title: BIORESORBABLE POLYMER MATRICES AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: ROYER BIOMEDICAL, INC

Application No.: 13/228267   Filing Date: 08/Sep/2011

Abstract:

A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition. The composition may be administered to a body site in need of the same by providing a first aliquot portion of a reaction mixture which includes the reactants and a bioactive agent. A kit which includes a double syringe respectively containing the first and second aliquot portions of the reaction mixture may be provided so that the same may be mixed just prior to use.

Priority: US2007-983454 Applic. Date: 2007-11-09; WO2006US02380 Applic. Date: 2006-01-23; US2005-684974P Applic. Date: 2005-05-27

Inventor: ROYER GARFIELD P [US]


Patent No.: US8440176B2  Issued: 14/May/2013

Title: COVALENTLY GRAFTED PHARMACEUTICALLY ACTIVE POLYMERS

Applicant/Assignee: INTERFACE BIOLOGICS, INC

Application No.: 12/429703   Filing Date: 24/Apr/2009

Abstract:

The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.

Priority: US2008-125459P Applic. Date: 2008-04-25

Inventor: LARONDE FRANK [CA]; GU FAN [CA]


Patent No.: US8440225B2  Issued: 14/May/2013

Title: Process of making flowable hemostatic compositions and devices containing such compositions

Applicant/Assignee: ETHICON, INC

Application No.: 11/264584   Filing Date: 01/Nov/2005

Abstract:

The present invention is directed to processes of making flowable hemostatic compositions and devices that include the flowable hemostatic composition disposed therein, where a volume of a biocompatible liquid, a volume of a biocompatible gas, and an amount of solid particles of a biocompatible polymer are mixed together to form a substantially homogenous composition including a discontinuous gas phase and the solid particles substantially homogenously dispersed throughout a continuous liquid phase to form a flowable hemostatic composition, and the composition then transferred into a device suitable for applying the flowable hemostatic composition to a site of a body requiring hemostasis under conditions effective to maintain the substantially homogeneous dispersion of the gas phase and the solid particles throughout the liquid phase,

wherein said transfer of said substantially homogenous hemostatic composition is conducted at an angle.

Priority: US2004-896454 Applic. Date: 2004-07-21; US2003-493116P Applic. Date: 2003-08-07

Inventor: GABEL JONATHAN B [US]; LOONEY DWAYNE L [US]; GUGLIELMO MICHAEL E [US]


Patent No.: US8440227B2  Issued: 14/May/2013

Title: Biodegradable, non-toxic biological adhesive and methods for use in abdominal surgery

Applicant/Assignee:

Application No.: 13/453468   Filing Date: 23/Apr/2012

Abstract:

A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing prosthesis during a hernia operation in a patient and occluding a fistula within a patient.

Priority: US2006-507623 Applic. Date: 2006-08-22; US2006-762136P Applic. Date: 2006-01-26

Inventor: CUETO-GARCIA JORGE [MX]


Patent No.: US8440731B2  Issued: 14/May/2013

Title: METHOD FOR PRODUCING FUNCTIONAL MATERIAL, FUNCTIONAL MATERIAL, SHEET-LIKE STRUCTURE AND SANITARY PRODUCT

Applicant/Assignee: UNICHARM CORPORATION

Application No.: 12/449087   Filing Date: 22/Jan/2008

Abstract:

Provided is a method for producing a functional material, including the steps of: bringing a polyvalent metal cation aqueous solution into contact with a base material

bringing a polyanion aqueous solution containing a functional component into contact with the base material previously in contact with the polyvalent metal cation aqueous solution to bond the polyvalent metal cations and the polyanions to each other, and thereby forming an insoluble compound containing the functional component

and drying the base material including the insoluble compound.

Priority: JP20070011969 Applic. Date: 2007-01-22; WO2008JP50822 Applic. Date: 2008-01-22

Inventor: ICHIURA HIDEAKI [JP]; MORIKAWA MASAAKI [JP]; TAKAHASHI MASAKI [JP]; NISHIDA NORIYOSHI [JP]; IGAUE TAKAMITSU [JP]; KONISHI TAKAYOSHI [JP]


Patent No.: US8445010B2  Issued: 21/May/2013

Title: ABUSE POTENTIAL REDUCTION IN ABUSABLE SUBSTANCE DOSAGE FORM

Applicant/Assignee: TRAVANTI PHARMA INC, TEIKOKU PHARMA USA, INC

Application No.: 12/976610   Filing Date: 22/Dec/2010

Abstract:

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Patent No.: US8445011B2  Issued: 21/May/2013

Title: DELAYED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

Applicant/Assignee: WELLESLEY PHARMACEUTICALS, LLC

Application No.: 13/560665   Filing Date: 27/Jul/2012

Abstract:

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

Priority: US201213487343 Applic. Date: 2012-06-04; US201213423949 Applic. Date: 2012-03-19; US201213343349 Applic. Date: 2012-01-04; US2010-956634 Applic. Date: 2010-11-30; US2010-362374P Applic. Date: 2010-07-08

Inventor: DILL DAVID A [US]


Patent No.: US8445015B2  Issued: 21/May/2013

Title: EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

Applicant/Assignee: WELLESLEY PHARMACEUTICALS, LLC

Application No.: 13/560607   Filing Date: 27/Jul/2012

Abstract:

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.

Priority: US201213487348 Applic. Date: 2012-06-04; US201213424000 Applic. Date: 2012-03-19; US201213343332 Applic. Date: 2012-01-04; US2010-956634 Applic. Date: 2010-11-30; US2010-362374P Applic. Date: 2010-07-08

Inventor: DILL DAVID A [US]


Patent No.: US8449868B2  Issued: 28/May/2013

Title: Preparation of cationic nanoparticles and personal care compositions comprising said nanoparticles

Applicant/Assignee: BASF SE

Application No.: 12/378567   Filing Date: 17/Feb/2009

Abstract:

The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also contribute useful conditioning properties to hair-care and skin-care products.

Priority: US2008-066599P Applic. Date: 2008-02-21

Inventor: JENNINGS JOHN [IE]; HUEGLIN DIETMAR [DE]; MAO JIANWEN [US]; MUEHLEBACH ANDREAS [CH]


Patent No.: US8449913B2  Issued: 28/May/2013

Title: Methods of Administering a Dermatological Agent to a Subject

Applicant/Assignee: TEIKOKU PHARMA USA, INC, TEIKOKU SEIYAKU KABUSHIKI KAISHA

Application No.: 12/767638   Filing Date: 26/Apr/2010

Abstract:

Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

Priority: US2004-754477 Applic. Date: 2004-01-08; US2003-445572P Applic. Date: 2003-02-07

Inventor: KOO JOHN [US]; SHUDO JUTARO [US]; SHIRAI SADANOBU [JP]


Patent No.: US8450287B2  Issued: 28/May/2013

Title: TOPICAL OPHTHALMIC COMPOSITIONS CONTAINING TOBRAMYCIN AND DEXAMETHASONE

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: 13/311716   Filing Date: 06/Dec/2011

Abstract:

Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.

Priority: US2010-841414 Applic. Date: 2010-07-22; US2007-960196 Applic. Date: 2007-12-19

Inventor: KABRA BHAGWATI P [US]


Patent No.: US8450380B2  Issued: 28/May/2013

Title: METHOD FOR IMPLEMENTING ACTIVE INGREDIENTS IN ORDER TO PROTECT THEM AND OPTIMIZE THEIR DELIVERY METHOD

Applicant/Assignee: COATEX S.A.S

Application No.: 12/524577   Filing Date: 30/Jan/2008

Abstract:

The invention pertains to a new method for formulating pharmaceutical active ingredients in such a way as to protect them when ingested orally, and to allow for the controlling of the release of the active ingredient in the intestine. It relies upon the use of thickening acrylic emulsions with a pH greater than 5, containing hydrophobic groups, in order to encapsulate the pharmaceutical active ingredients for the purpose of encouraging their passage through the gastrointestinal barrier, while controlling the release kinetics of said active ingredients.

Priority: FR20070000926 Applic. Date: 2007-02-09; WO2008IB00261 Applic. Date: 2008-01-30

Inventor: GUERRET OLIVIER [FR]; SUAU JEAN-MARC [FR]


Patent No.: US8450390B2  Issued: 28/May/2013

Title: METHODS FOR THE FORMATION OF HYDROGELS USING THIOSULFONATE COMPOSITIONS AND USES THEREOF

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 13/554292   Filing Date: 20/Jul/2012

Abstract:

The present invention provides both crosslinked polymer compositions capable of forming hydrogels upon exposure to an aqueous environment and thiosulfonate hydrogel-forming components. The thiosulfonate hydrogel-forming components of the invention are preferably multi-arm thiosulfonate polymer derivatives that form a crosslinked polymer composition when exposed to a base without requiring the presence of a second cross-linking reagent, redox catalyst, or radiation. Methods for forming hydrogel compositions, as well as methods for using the hydrogels, are also provided.

Priority: US201113325936 Applic. Date: 2011-12-14; US2009-547369 Applic. Date: 2009-08-25; US2007-904985 Applic. Date: 2007-09-27; US2003-751010 Applic. Date: 2003-12-31; US2002-437252P Applic. Date: 2002-12-31

Inventor: FANG ZHIHAO [US]; BENTLEY MICHAEL D [US]


Patent No.: US8450475B2  Issued: 28/May/2013

Title: Hyaluronic Acid-Based Gels Including Lidocaine

Applicant/Assignee: ALLERGAN, INC

Application No.: 12/393768   Filing Date: 26/Feb/2009

Abstract:

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Priority: US2008-085956P Applic. Date: 2008-08-04; US2008-087934P Applic. Date: 2008-08-11; US2008-096278P Applic. Date: 2008-09-11

Inventor: LEBRETON PIERRE F [FR]


Patent No.: US8454989B2  Issued: 04/Jun/2013

Title: Laminated ingestible dosage form for dispensing multiple bioactive substances

Applicant/Assignee: HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P

Application No.: 11/111240   Filing Date: 20/Apr/2005

Abstract:

A method of manufacturing a bioactive fluid dose on an ingestible sheet, comprising the steps of advancing the ingestible sheet to a dispense position, and activating a fluid ejector to dispense essentially a drop of a bioactive fluid onto the ingestible sheet.

Priority: US2001-028450 Applic. Date: 2001-10-24

Inventor: LEE BRIAN CRAIG [US]; STEINFIELD STEVEN W [US]; CHILDERS WINTHROP D [US]; VAN VEEN MARK A [US]; SAMII MOHAMMAD M [US]


Patent No.: US8455013B2  Issued: 04/Jun/2013

Title: Use of an extract of common mallow as an hydrating agent, and cosmetic composition containing it

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/500824   Filing Date: 10/Jul/2009

Abstract:

The present invention relates to a novel use of an extract of common mallow for restoring, maintaining or reinforcing the state of moisturization of the skin

to a cosmetic composition containing it, and also to cosmetic care methods using said composition.

Priority: FR20080054780 Applic. Date: 2008-07-11

Inventor: DUMAS MARC [FR]; NOBLESSE EMMANUELLE [FR]; KRZYCH VALERIE [FR]; CAUCHARD JEAN HUBERT [FR]


Patent No.: US8455554B2  Issued: 04/Jun/2013

Title: METAL OXIDE HYDROGELS AND HYDROSOLS, THEIR PREPARATION AND USE

Applicant/Assignee: CAPTIGEL AB

Application No.: 12/304513   Filing Date: 12/Jun/2007

Abstract:

A process for preparing a hydrosol of one or more metal oxides, e.g. titanium dioxide, comprising preparing a metal alkoxide solution in a water-miscible organic solvent, e.g. an alcohol

providing an aqueous solvent

mixing the metal alkoxide solution with the aqueous solvent in a volume or weight proportion to form a single-phase aqueous sol colloid (hydrosol) of hydrated metal oxide in absence of a non-ionic block polymer surfactant. Also disclosed is a corresponding hydrogel

water-insoluble particles encapsulated in hydrated metal oxide and a process for their encapsulation

uses of the encapsulation products.

Priority: US2006-812779P Applic. Date: 2006-06-12; WO2007SE00577 Applic. Date: 2007-06-12

Inventor: KESSLER VADIM G [SE]; SEISENBAEVA GULAIM A [SE]; HAAKANSSON SEBASTIAN [SE]; UNELL MARIA [SE]


Patent No.: US8460642B2  Issued: 11/Jun/2013

Title: BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH

Applicant/Assignee: OSTEOGENEX, INC, OSSIFI, INC

Application No.: 13/456060   Filing Date: 25/Apr/2012

Abstract:

The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.

Priority: US2009-571623 Applic. Date: 2009-10-01; US2008-102084P Applic. Date: 2008-10-02

Inventor: ELLIES DEBRA [US]; ROSENBERG WILLIAM [US]


Patent No.: US8460686B2  Issued: 11/Jun/2013

Title: BIOACTIVE BONE GRAFT SUBSTITUTE

Applicant/Assignee: ORTHOVITA, INC

Application No.: 13/627439   Filing Date: 26/Sep/2012

Abstract:

The invention relates to biocompatible bone graft materials for repairing bone defects and the application of such bone grafts. The devices of the invention comprise resorbable calcium phosphate, resorbable collagen and bioactive glasses.

Priority: US2007-771857 Applic. Date: 2007-06-29; US2006-817617P Applic. Date: 2006-06-29

Inventor: CLINEFF THEODORE D [US]; KOBLISH ANTONY [US]; BAGGA CHARANPREET S [US]; ERBE ERIK M [US]; NAGVAJARA GINA M [US]; DARMOC MARISSA M [US]


Patent No.: US8460708B2  Issued: 11/Jun/2013

Title: COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE

Applicant/Assignee: ANGIODEVICE INTERNATIONAL GMBH

Application No.: 13/279987   Filing Date: 24/Oct/2011

Abstract:

Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

Priority: US2005-118088 Applic. Date: 2005-04-28; US2004-566569P Applic. Date: 2004-04-28

Inventor: DANILOFF GEORGE Y [US]; SEHL LOUIS C [US]; TROLLSAS OLOF MIKAEL [US]; SCHROEDER JACQUELINE A [US]; GRAVETT DAVID M [US]; TOLEIKIS PHILIP M [US]


Patent No.: US8465772B2  Issued: 18/Jun/2013

Title: METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 13/472324   Filing Date: 15/May/2012

Abstract:

Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier.

In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

Priority: US2006-566643 Applic. Date: 2006-12-04

Inventor: HOSSAINY SYED [US]; NGO MICHAEL [US]; TROLLSAS MIKAEL [US]; STANKUS JOHN [US]; MICHAL GENE [US]


Patent No.: US8465773B2  Issued: 18/Jun/2013

Title: METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEM INC, ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 13/472328   Filing Date: 15/May/2012

Abstract:

Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier.

In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

Priority: US2006-566643 Applic. Date: 2006-12-04

Inventor: HOSSAINY SYED [US]; NGO MICHAEL [US]; TROLLSAS MIKAEL [US]; STANKUS JOHN [US]; MICHAL GENE [US]


Patent No.: US8470344B2  Issued: 25/Jun/2013

Title: Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/433013   Filing Date: 12/May/2006

Abstract:

The present invention encompasses a method of preparing a ready-to-dissolve or ready-to-disperse composition of difficult to dissolve in water compounds and suspensions or aqueous solutions of difficult to dissolve in water compounds.

Priority: US2005-749244P Applic. Date: 2005-12-09

Inventor: BERSHTEYN YOSEF [IL]; FAINGERSH ANNA [IL]


Patent No.: US8470359B2  Issued: 25/Jun/2013

Title: Sustained release polymer

Applicant/Assignee: QLT USA, INC

Application No.: 11/469392   Filing Date: 31/Aug/2006

Abstract:

A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.

Priority: US2004-872671 Applic. Date: 2004-06-21; US2003-373400 Applic. Date: 2003-02-24; US2000-711758 Applic. Date: 2000-11-13

Inventor: DUNN RICHARD L [US]


Patent No.: US8470368B2  Issued: 25/Jun/2013

Title: Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Applicant/Assignee: WATSON PHARMACEUTICALS, INC

Application No.: 13/151653   Filing Date: 02/Jun/2011

Abstract:

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Priority: US2004-777542 Applic. Date: 2004-02-12; US2003-664803 Applic. Date: 2003-09-19; US2002-412181P Applic. Date: 2002-09-20; US2002-412180P Applic. Date: 2002-09-20

Inventor: KOSITPRAPA UNCHALEE [US]; GOLDFARB ROBERT I [US]; CARDINAL JOHN R [US]; NANGIA AVINASH [US]


Patent No.: US8470370B2  Issued: 25/Jun/2013

Title: Controlled Release Formulations

Applicant/Assignee: THE UAB RESEARCH FOUNDATION, AEGIS THERAPEUTICS, LLC

Application No.: 13/688116   Filing Date: 28/Nov/2012

Abstract:

The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.

Priority: US2008-197179 Applic. Date: 2008-08-22; US2008-188441P Applic. Date: 2008-08-07; US2008-086743P Applic. Date: 2008-08-06; US2007-957960P Applic. Date: 2007-08-24

Inventor: MAGGIO EDWARD T [US]; MEEZAN ELIS [US]; PILLION DENNIS J [US]; MORGAN SARAH L [US]; BAGGOTT JOE [US]


Patent No.: US8470881B2  Issued: 25/Jun/2013

Title: SYSTEM FOR TRAPPING FLYING INSECTS WITH ATTRACTANT LURES

Applicant/Assignee: WOODSTREAM CORPORATION

Application No.: 13/305543   Filing Date: 28/Nov/2011

Abstract:

The present application discloses a system for trapping flying insects, a first chemical lure such as lactic acid, a salt of lactic acid, or combinations thereof, and a second chemical lure comprising a source of ammonia. The lures may be employed in particular geometric shapes contained in specifically designed housing to ensure an effective release rate over extended periods of time.

Priority: US2004-864284 Applic. Date: 2004-06-08; US2003-431586 Applic. Date: 2003-05-08; US2002-378369P Applic. Date: 2002-05-08

Inventor: DURAND EMMA A [US]; CAO MIAOYONG [US]; LIU CUIXIA [US]; DUNNE RICHARD B [US]


Patent No.: US8475832B2  Issued: 02/Jul/2013

Title: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

Applicant/Assignee: MONOSOL RX, LLC, RB PHARMACEUTICALS LIMITED

Application No.: 12/537571   Filing Date: 07/Aug/2009

Abstract:

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Priority:

Inventor: MYERS GARRY L [US]; HILBERT SAMUEL D [US]; BOONE BILL J [US]; BOGUE B ARLIE [US]; SANGHVI PRADEEP [US]; HARIHARAN MADHUSUDAN [US]


Patent No.: US8475837B2  Issued: 02/Jul/2013

Title: Abuse Potential Reduction in Abusable Substance Dosage Form

Applicant/Assignee: TRAVANTI PHARMA INC, TEIKOKU PHARMA USA, INC

Application No.: 12/952516   Filing Date: 23/Nov/2010

Abstract:

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Patent No.: US8481013B2  Issued: 09/Jul/2013

Title: COMPOUNDS HAVING SANDALWOOD ODORS

Applicant/Assignee: FIRMENICH SA

Application No.: 13/123776   Filing Date: 18/Nov/2009

Abstract:

Sandalwood perfuming ingredients that are 2-[perhydro-trialkyl-2-naphthalenylidene]-1-propanol or propanal derivatives of the formula wherein one dotted line represents a carbon-carbon single bond and the other a carbon-carbon single bond or double bond

X represents a CH2OH group or a CHO group

each R1 represents a hydrogen atom or a methyl group

and the R2, taken separately, represent each a hydrogen atom or the two R2 groups, taken together, represent a CH2 group or a carbon-carbon double bond

and said compound is in the form of any one of its stereoisomers or a mixture thereof, along with the use of such compound(s) in perfuming compositions or articles in the perfumery industry.

Priority: WO2008IB54962 Applic. Date: 2008-11-26; WO2009IB55142 Applic. Date: 2009-11-18

Inventor: CHAPUIS CHRISTIAN [CH]


Patent No.: US8481058B2  Issued: 09/Jul/2013

Title: Topical composition, topical composition precursor, and methods for manufacturing and using

Applicant/Assignee: SKINVISIBLE PHARMACEUTICALS, INC

Application No.: 10/154723   Filing Date: 23/May/2002

Abstract:

A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.

Priority: US2001-933275 Applic. Date: 2001-08-20

Inventor: JEZIOR BRUCE [US]


Patent No.: US8481071B2  Issued: 09/Jul/2013

Title: HYDROGEL COMPOSITIONS WITH AN ERODIBLE BACKING MEMBER

Applicant/Assignee: A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, CORIUM INTERNATIONAL, INC

Application No.: 13/482965   Filing Date: 29/May/2012

Abstract:

A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Priority: US2003-661103 Applic. Date: 2003-09-12; US2003-359548 Applic. Date: 2003-02-05; US2002-137664 Applic. Date: 2002-05-01; US2001-288008P Applic. Date: 2001-05-01

Inventor: SINGH PARMINDER [US]; FAASSE ADRIAN [US]; CLEARY GARY W [US]; MUDUMBA SRI [US]; FELDSTEIN MIKHAIL M [RU]; BAIRAMOV DANIR F [RU]


Patent No.: US8481079B2  Issued: 09/Jul/2013

Title: Drug delivery system based on polyethylene vinylacetate copolymers

Applicant/Assignee: N.V. ORGANON, MERCK SHARP & DOHME B.V

Application No.: 10/594104   Filing Date: 16/Mar/2005

Abstract:

Disclosed herein is a drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer. Also disclosed are a contraceptive kit or hormone-replacement therapy kit comprising the drug delivery system, and a combination preparation that simultaneously provides contraception and treatment of a sexually transmitted disease comprising the drug delivery system.

Priority: EP20040101215 Applic. Date: 2004-03-24; WO2005EP51189 Applic. Date: 2005-03-16

Inventor: DE GRAAFF WOUTER [NL]; GROEN JANNEKE SOPHIE [NL]; KRUFT MARCUS ANTONIUS BERNARDUS [NL]; VAN LAARHOVEN JOHANNES ANTONIUS HENDRIKUS [NL]; VROMANS HERMAN [NL]; ZEEMAN RAYMOND [NL]


Patent No.: US8481080B2  Issued: 09/Jul/2013

Title: Method of cross-linking hyaluronic acid with divinulsulfone

Applicant/Assignee: NOVOZYMES BIOPOLYMER, NOVOZYMES BIOPOLYMER A/S

Application No.: 11/719790   Filing Date: 24/Nov/2005

Abstract:

The present invention relates to methods of producing a homogenous hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with divinylsulfone (DVS), said method comprising the steps of (a) providing an alkaline solution of hyaluronic acid, or salt thereof

(b) adding DVS to the solution of step (a), whereby the hyaluronic acid, or salt thereof, is crosslinked with the DVS to form a gel

(c) treating the gel of step (b) with a buffer, wherein the gel swells and forms a hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with DVS.

Priority: DK20040001824 Applic. Date: 2004-11-24; US2004-630620P Applic. Date: 2004-11-24; WO2005DK00753 Applic. Date: 2005-11-24

Inventor: LONGIN FANNY [DK]; SCHWACH-ABDELLAOUI KHADIJA [DK]


Patent No.: US8486454B2  Issued: 16/Jul/2013

Title: Method of attenuating neurogenic pain

Applicant/Assignee: FERRIS PHARMACEUTICALS, INC, SESSIONS PHARMACEUTICALS INC

Application No.: 11/540460   Filing Date: 29/Sep/2006

Abstract:

The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic pain.

Priority: US2006-440550 Applic. Date: 2006-05-25; US2002-175119 Applic. Date: 2002-06-19; US2001-789275 Applic. Date: 2001-02-20; US1999-326836 Applic. Date: 1999-06-07; US1998-088424P Applic. Date: 1998-06-08

Inventor: SESSIONS ROBERT W [US]; KAHN ALAN R [US]


Patent No.: US8486455B2  Issued: 16/Jul/2013

Title: POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY

Applicant/Assignee: QLT USA, INC, TOLMAR THERAPEUTICS, INC

Application No.: 12/784304   Filing Date: 20/May/2010

Abstract:

The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.

Priority: US2006-643505 Applic. Date: 2006-12-21; US2004-872671 Applic. Date: 2004-06-21; US2003-373400 Applic. Date: 2003-02-24; US2000-711758 Applic. Date: 2000-11-13; US2000-666174 Applic. Date: 2000-09-21; US2000-643289 Applic. Date: 2000-08-22; US1998-181355 Applic. Date: 1998-10-28

Inventor: DUNN RICHARD L [US]; GARRETT JOHN STEVEN [US]; RAVIVARAPU HARISH [US]; CHANDRASHEKAR BHAGYA L [US]


Patent No.: US8491890B2  Issued: 23/Jul/2013

Title: Methods and Compositions for Inhibiting Diseases of the Central Nervous System

Applicant/Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Application No.: 12/500414   Filing Date: 09/Jul/2009

Abstract:

Methods and compositions for treating central nervous system diseases and disorders are disclosed.

Priority: US2008-134350P Applic. Date: 2008-07-09; US2009-208090P Applic. Date: 2009-02-20

Inventor: GENDELMAN HOWARD E [US]; MOSLEY R LEE [US]; REYNOLDS ASHLEY D [US]


Patent No.: US8491935B2  Issued: 23/Jul/2013

Title: Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes

Applicant/Assignee: TRIS PHARMA, INC

Application No.: 13/666424   Filing Date: 01/Nov/2012

Abstract:

A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.

Priority: US2010-722857 Applic. Date: 2010-03-12; US2007-724966 Applic. Date: 2007-03-15; US2006-783181P Applic. Date: 2006-03-16

Inventor: MEHTA KETAN [US]; TU YU-HSING [US]


Patent No.: US8492151B1  Issued: 23/Jul/2013

Title: Processes and compositions for transfecting chinese hamster ovary (CHO) cells

Applicant/Assignee: LEINCO TECHNOLOGIES, INC

Application No.: 12/780883   Filing Date: 15/May/2010

Abstract:

The present invention generally relates to processes and compositions for the transfection of Chinese hamster ovary (CHO) cells. More specifically, the present invention relates to processes for the transfection of CHO cells suspended in an aqueous medium using a transfection composition containing nucleic acid and linear polyethyleneimine.

Priority: US2007-750401 Applic. Date: 2007-05-18; US2006-846664P Applic. Date: 2006-09-22; US2006-843186P Applic. Date: 2006-09-08; US2006-802914P Applic. Date: 2006-05-24; US2006-802041P Applic. Date: 2006-05-19

Inventor: HAMM SARAH E [US]; LEINERT WILLIAM P [US]


Patent No.: US8496946B2  Issued: 30/Jul/2013

Title: ANTIMICROBIAL HYDROGELS, METHODS OF PREPARATION THEREOF, AND ARTICLES THEREFROM

Applicant/Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATION

Application No.: 13/213555   Filing Date: 19/Aug/2011

Abstract:

A covalently crosslinked hydrogel comprises a) three or more divalent poly(alkylene oxide) chains P' covalently linked at respective first end units to a branched first core group C', b) three or more divalent poly(alkylene oxide) chains P'' covalently linked at respective first end units to a branched second core group C'', the chains P'' comprising respective second end units which are covalently linked to between 0% and 100% of respective second end units of chains P' by divalent linking groups L'', and c) at least one pendant cationic block copolymer chain A'-B'.

A'-B' comprises i) a divalent block A' comprising a poly(alkylene oxide) backbone chain having an end unit covalently linked to a second end unit of one of the chains P' by a divalent linking group L', and ii) a monovalent block B' comprising a first repeat unit, the first repeat unit comprising a backbone carbonate group and a cationic side chain group.

Priority: US201161451491P Applic. Date: 2011-03-10

Inventor: COADY DANIEL JOSEPH [US]; ENGLER AMANDA CATHERINE [US]; HEDRICK JAMES LUPTON [US]; LIU SHAOQIONG [SG]; YANG YI YAN [SG]; YANG CHUAN [SG]


Patent No.: US8496954B2  Issued: 30/Jul/2013

Title: Coating systems for the controlled delivery of hydrophilic bioactive agents

Applicant/Assignee: SURMODICS, INC

Application No.: 12/386469   Filing Date: 17/Apr/2009

Abstract:

Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents

and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer.

Priority: US2008-124675P Applic. Date: 2008-04-18

Inventor: CHAPPA RALPH A [US]; HERGENROTHER ROBERT W [US]; WADMAN SHANNON A [US]; WORMUTH KLAUS R [US]


Patent No.: US8496958B2  Issued: 30/Jul/2013

Title: COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE

Applicant/Assignee: NATURAL ALTERNATIVES INTERNATIONAL, INC, WOLF KEN

Application No.: 13/755954   Filing Date: 31/Jan/2013

Abstract:

Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.

Priority: US201213646184 Applic. Date: 2012-10-05; US2009-064005 Applic. Date: 2009-04-30; WO2006US20104 Applic. Date: 2006-05-23; US2005-683985P Applic. Date: 2005-05-23

Inventor: HARRIS ROGER [GB]; WISE JOHN [US]


Patent No.: US8501229B2  Issued: 06/Aug/2013

Title: HYDROPHOBIC CROSS-LINKED GELS FOR BIOABSORBABLE DRUG CARRIER COATINGS

Applicant/Assignee: ATRIUM MEDICAL CORPORATION

Application No.: 13/404487   Filing Date: 24/Feb/2012

Abstract:

Coatings for medical devices, methods of making the coatings, and methods of using them are described.

Priority: US2006-582135 Applic. Date: 2006-10-16; US2005-727312P Applic. Date: 2005-10-15

Inventor: FAUCHER KEITH M [US]; TANG HUI [US]; ROGERS LISA [US]; FERRARO JOSEPH [US]; MARTAKOS PAUL [US]; HERWECK STEVE A [US]; KARWOSKI THEODORE [US]


Patent No.: US8507430B2  Issued: 13/Aug/2013

Title: METHODS FOR ADMINISTERING FGF18

Applicant/Assignee: ZYMOGENETICS, INC

Application No.: 12/104285   Filing Date: 16/Apr/2008

Abstract:

FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.

Priority: US2003-680673 Applic. Date: 2003-10-07; US2002-416670P Applic. Date: 2002-10-07

Inventor: ELLSWORTH JEFF L [US]


Patent No.: US8507564B2  Issued: 13/Aug/2013

Title: Method For Selecting Perfume Ingredient, Method For Formulating Fragrance, And Preference-Enhancing Agent

Applicant/Assignee: SHISEIDO CO., LTD

Application No.: 11/997770   Filing Date: 01/Aug/2006

Abstract:

Methods for enhancing a preference for a product by repetitive use. The method involves formulating a perfume composition into a product, the perfume composition including (I) allyl caproate and (II) ambroxan or geranium oil.

Priority: JP20050227120 Applic. Date: 2005-08-04; JP20060076721 Applic. Date: 2006-03-20; JP20060076722 Applic. Date: 2006-03-20; JP20060076723 Applic. Date: 2006-03-20; WO2006JP315212 Applic. Date: 2006-08-01

Inventor: SHOJI KEN [JP]; TAGUCHI SUMIE [JP]; TERAJIMA YUSHI [JP]; HASHIMOTO KATSUO [JP]


Patent No.: US8512693B2  Issued: 20/Aug/2013

Title: Self-Assembling Membranes And Related Methods Thereof

Applicant/Assignee: NORTHWESTERN UNIVERSITY

Application No.: 12/031421   Filing Date: 14/Feb/2008

Abstract:

The present invention relates to self-assembling membranes. In particular, the present invention provides self-assembling membranes configured for securing and/or delivering bioactive agents. In some embodiments, the self-assembling membranes are used in the treatment of diseases, and related methods (e.g., diagnostic methods, research methods, drug screening).

Priority: US2007-901612P Applic. Date: 2007-02-14

Inventor: CAPITO RAMILLE M [US]; AZEVEDO HELENA S [PT]; STUPP SAMUEL I [US]


Patent No.: US8512749B2  Issued: 20/Aug/2013

Title: Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use

Applicant/Assignee: INCEPT LLC, INCEPT, LLC

Application No.: 10/795132   Filing Date: 05/Mar/2004

Abstract:

Compositions and methods are provided for forming tissue-adherent hydrogels using substantially dry precursors. The dehydrated precursors are premixed prior to in situ therapy and utilize naturally-occurring body fluids as an aqueous environment that initiates transformation, which causes dissolution and nearly simultaneous crosslinking of the precursors, thus forming an insoluble hydrogel implant. The dehydrated precursor-based hydrogels may be used as sealants for fluid leaks from tissue, as adherent drug delivery depots, as means for augmenting and/or supporting tissue, and as means for serving a variety of other useful medical and surgical purposes.

Priority: US2001-776120 Applic. Date: 2001-02-02

Inventor: SAWHNEY AMARPREET S [US]; EDELMAN PETER G [US]; BENNETT STEVEN L [US]


Patent No.: US8513311B2  Issued: 20/Aug/2013

Title: Oil-In-Water Emulsion and Its Use for the Delivery of Functionality

Applicant/Assignee: NESTEC S.A

Application No.: 12/093560   Filing Date: 22/Nov/2006

Abstract:

The present invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structurization with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic additive and the oil-in-water emulsion contains an active element being present in the range comprised between 0.00001 and 79% based on the total composition.

Priority: EP20050025439 Applic. Date: 2005-11-22; WO2006EP68761 Applic. Date: 2006-11-22

Inventor: SAGALOWICZ LAURENT [CH]; LESER MARTIN [CH]; MICHEL MARTIN [CH]; WATZKE HERIBERT JOHANN [CH]; ACQUISTAPACE SIMONE [CH]; BERTHOLET RAYMOND [CH]; HOLST BIRGIT [FR]; ROBERT FABIEN [FR]


Patent No.: US8518381B2  Issued: 27/Aug/2013

Title: Processes of Making Oral Compositions Containing Gel Networks

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 12/410909   Filing Date: 25/Mar/2009

Abstract:

The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel network is formed when the fatty amphiphile dispersion is combined with the swelling surfactant. A method of preparing the fatty amphiphile dispersion and oral composition is included.

Priority: US2008-072201P Applic. Date: 2008-03-28

Inventor: LEBLANC MICHAEL JUDE [US]; DECKNER GEORGE ENDEL [US]


Patent No.: US8519010B2  Issued: 27/Aug/2013

Title: ANTIMICROBIAL COMPOSITIONS

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/097281   Filing Date: 29/Apr/2011

Abstract:

What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.

Priority: US2004-820349 Applic. Date: 2004-04-08

Inventor: MERIANOS JOHN J [US]; GARELICK PAUL [US]; LINDSTROM SUSAN M [US]


Patent No.: US8524256B2  Issued: 03/Sep/2013

Title: Deodorant cosmetic composition comprising at least one semicrystalline polymer

Applicant/Assignee: AIR PRODUCTS AND CHEMICALS, INC

Application No.: 10/874733   Filing Date: 24/Jun/2004

Abstract:

The disclosure relates to a deodorant composition comprising a physiologically acceptable water-in-oil emulsion carrier comprising at least one antiperspirant ingredient and at least one semicrystalline polymer having a melting point greater than or equal to 30 DEG C. The disclosure further relates to the use of cosmetic products for topical application to humans, such as deodorant products, and to methods of treating human perspiration and body odors associated with human perspiration. This composition may be in the form of a cosmetic cream having a very pleasant texture on application to the skin.

Priority: FR20030007804 Applic. Date: 2003-06-27; US2003-516739P Applic. Date: 2003-11-04

Inventor: PRUD HOMME ESTELLE [FR]; DOUIN VERONIQUE [FR]


Patent No.: US8524262B2  Issued: 03/Sep/2013

Title: Amphiphilic High Refractive Index Organopolysiloxanes

Applicant/Assignee: WACKER CHEMICAL CORPORATION

Application No.: 13/032883   Filing Date: 23/Feb/2011

Abstract:

Amphiphilic silicons which are dispersible or self-dispersing in water, have a high refractive index, and are prepared by a hydrosilylation reaction, resulting in products which are free of cyclic organopolysiloxanes. The high refractive index and dispersibility make the amphiphilic silicones useful in personal care and cosmetics where high shine or gloss is desired.

Priority:

Inventor: ROY AROOP KUMAR [US]; COFFEY MICHAEL LEE [US]


Patent No.: US8524759B2  Issued: 03/Sep/2013

Title: PHENYLBUTAZONE CARRIER FORMULATION SHOWING INCREASED BIOACTIVITY IN ANIMALS

Applicant/Assignee:

Application No.: 13/543948   Filing Date: 09/Jul/2012

Abstract:

An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.

Priority: US2009-608913 Applic. Date: 2009-10-29; US2009-227282P Applic. Date: 2009-07-21

Inventor: GORDON DOUGLAS J [US]


Patent No.: US8524783B2  Issued: 03/Sep/2013

Title: POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER

Applicant/Assignee: INTEZYNE TECHNOLOGIES, INCORPORATED

Application No.: 12/771676   Filing Date: 30/Apr/2010

Abstract:

The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Priority: US2009-174160P Applic. Date: 2009-04-30; US2009-178630P Applic. Date: 2009-05-15

Inventor: SILL KEVIN N [US]; SKAFF HABIB [US]; RIOS-DORIA JONATHAN [US]; CARDOEN GREGOIRE [FR]


Patent No.: US8524784B2  Issued: 03/Sep/2013

Title: POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER

Applicant/Assignee: INTEZYNE TECHNOLOGIES, INCORPORATED

Application No.: 12/915446   Filing Date: 29/Oct/2010

Abstract:

The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.

Priority: US2010-771676 Applic. Date: 2010-04-30; US2009-178630P Applic. Date: 2009-05-15; US2009-174160P Applic. Date: 2009-04-30

Inventor: SILL KEVIN N [US]; SKAFF HABIB [US]; RIOS-DORIA JONATHAN [US]


Patent No.: US8529939B2  Issued: 10/Sep/2013

Title: Mucoadhesive drug delivery devices and methods of making and using thereof

Applicant/Assignee: GEL-DEL TECHNOLOGIES, INC

Application No.: 11/007053   Filing Date: 08/Dec/2004

Abstract:

The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.

Priority: US2003-527962P Applic. Date: 2003-12-08

Inventor: MASTERS DAVID B [US]; BERG ERIC P [US]


Patent No.: US8530526B2  Issued: 10/Sep/2013

Title: BIOBENEFICIAL COATING COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/874892   Filing Date: 02/Sep/2010

Abstract:

A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.

Priority: US2003-723043 Applic. Date: 2003-11-26

Inventor: PACETTI STEPHEN D [US]


Patent No.: US8535711B2  Issued: 17/Sep/2013

Title: MEDICATION DISPOSAL SYSTEM

Applicant/Assignee: TRAVANTI PHARMA, INC, TEIKOKU PHARMA USA, INC

Application No.: 12/412144   Filing Date: 26/Mar/2009

Abstract:

The potential for environmental release of unused and expired medications is reduced by the provision of a system and method for combining the unused or expired medication with an amount of activated carbon as part of a disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Patent No.: US8535719B2  Issued: 17/Sep/2013

Title: Biohybrid elastomeric scaffolds and methods of use thereof

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: 11/825540   Filing Date: 06/Jul/2007

Abstract:

Provided herein is a biohybrid elastomeric scaffold comprising a synthetic polymeric component and a biological polymeric component. The scaffold can be fabricated to have many different forms, non-limiting examples of which include a non-woven fibrous mesh or in a porous composite. Methods of use of the biohybrid elastomeric scaffolds in wound healing and tissue regeneration are also provided.

Priority: US2006-806762P Applic. Date: 2006-07-07

Inventor: BADYLAK STEPHEN F [US]; FREYTES DONALD O [US]; GILBERT THOMAS W [US]; GUAN JIANJUN [US]; STANKUS JOHN [US]; WAGNER WILLIAM R [US]


Patent No.: US8535728B2  Issued: 17/Sep/2013

Title: Colloidal silver composition having antimicrobial properties

Applicant/Assignee: AMERICAN SILVER, LLC

Application No.: 10/563688   Filing Date: 03/Jun/2004

Abstract:

Colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described. The composition can be incorporated into a hydrogel with essentially no loss of antimicrobial properties.

Priority: US2001-946834 Applic. Date: 2001-09-04; US1999-323310 Applic. Date: 1999-06-01; US2003-475657P Applic. Date: 2003-06-03; WO2004US17567 Applic. Date: 2004-06-03

Inventor: HOLLADAY ROBERT J [US]; CHRISTENSEN HERBERT [US]; MOELLER WILLIAM [US]


Patent No.: US8536230B2  Issued: 17/Sep/2013

Title: Methods for Regulating Gelation of Polysaccharide Solutions and Uses Thereof

Applicant/Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 12/162057   Filing Date: 25/Jan/2007

Abstract:

The present invention provides a method for preparing chitosan solutions to allow regulating the conditions in which the chitosan solution will gel. The present invention also provides methods for using chitosan solutions as compositions and for using chitosan solutions in vitro and in vivo.

Priority: US2006-762084P Applic. Date: 2006-01-25; WO2007US01896 Applic. Date: 2007-01-25

Inventor: LAURENCIN CATO T [US]; NAIR LAKSHMI SREEDHARAN [US]


Patent No.: US8541027B2  Issued: 24/Sep/2013

Title: Fixation devices for tissue repair

Applicant/Assignee: SMITH & NEPHEW, INC

Application No.: 10/479746   Filing Date: 31/May/2002

Abstract:

Fixation devices for tissue repair, for example sutures, surgical arrows, staples, darts, bolts, screws, buttons, anchors, nails, rivets or barbed devices comprise at least one of angiogenic material

angiogenic precursor material which is capable of breaking down in vivo to form angiogenic material

and tissue-engineered material, which tissue-engineered material is capable of producing angiogenic material. In a preferred form the material is incorporated into a polymer matrix having predetermined hydrophobicity to allow controlled release of angiogenic materials such as butyric or hydroxybutyric acid or salts thereof. Polymer matrix compositions comprising angiogenic materials and methods for tissue repair are also provided.

Priority: GB20010013697 Applic. Date: 2001-06-06; WO2002GB02602 Applic. Date: 2002-05-31

Inventor: WRIGHT EMMA JAYNE [GB]; HUCKLE JAMES WILLIAM [GB]; ALI SAAD ABOUL MAJEED [GB]


Patent No.: US8541028B2  Issued: 24/Sep/2013

Title: Methods for manufacturing delivery devices and devices thereof

Applicant/Assignee: EVONIK CORPORATION

Application No.: 11/196591   Filing Date: 03/Aug/2005

Abstract:

Described herein are methods for reducing and achieving the desired release of an agent from a delivery system. The desired release kinetics are achieved by exposing the surface of the delivery system with a fluid for a desired period of time.

Priority: US2004-599174P Applic. Date: 2004-08-04

Inventor: STAAS JAY K [US]; TICE THOMAS R [US]; HUDSON BRUCE W [US]; TIPTON ARTHUR J [US]


Patent No.: US8541029B2  Issued: 24/Sep/2013

Title: ARTICLE AND METHOD FOR FOCUSED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC MATERIALS

Applicant/Assignee: ARMARK AUTHENTICATION TECHNOLOGIES, LLC

Application No.: 13/337570   Filing Date: 27/Dec/2011

Abstract:

A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.

Priority: US2008-342830 Applic. Date: 2008-12-23; US2006-578695 Applic. Date: 2006-10-17; US2007-017815P Applic. Date: 2007-12-31

Inventor: GABRIELE PETER D [US]; FLEMMENS MICHAEL S [US]; ROBERTSON JEFFREY H [US]; HOGAN ANDREW [US]


Patent No.: US8545824B2  Issued: 01/Oct/2013

Title: Glycerol Ether Mixture, Cosmetic Composition Containing this Mixture and Process for its Production

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/822671   Filing Date: 24/Jun/2010

Abstract:

The invention relates to a glycerol ether mixture which consists essentially of a) at least one C12-22 glycerol monoalkyl ether, b) at least one C12-22 glycerol dialkylether and optionally c) at least one C12-22 glycerol trialkyl ether and/or d) at least one C12-22 fatty alcohol, components a) and b) together making up at least 50% by weight of the glycerol ether mixture and the ratio by weight of component a) to component b) being in the range from 3:1 to 1:2. The invention also relates to a process for producing the glycerol ether mixture and to cosmetic compositions containing the glycerol ether mixture.

Priority: DE20041022252 Applic. Date: 2004-05-04; US2005-121392 Applic. Date: 2005-05-04

Inventor: NEUSS MICHAEL [DE]; ALBERS THOMAS [DE]; BRUENING STEFAN [US]; ANSMANN ACHIM [DE]; GONDEK HELGA [DE]; SCHMID KARL HEINZ [DE]


Patent No.: US8545832B2  Issued: 01/Oct/2013

Title: LIPID DEPOT FORMULATIONS

Applicant/Assignee: CAMURUS AB, CAMARUS AB

Application No.: 13/537096   Filing Date: 29/Jun/2012

Abstract:

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol

b) at least one phospholipid

c) at least one biocompatible, oxygen containing, low viscosity organic solvent

wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents.

The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Priority: GB20040012530 Applic. Date: 2004-06-04; GB20050000807 Applic. Date: 2005-01-14; GB20050007811 Applic. Date: 2005-04-18; US2007-628007 Applic. Date: 2007-07-24; WO2005GB02217 Applic. Date: 2005-06-06

Inventor: THURESSON KRISTER [SE]; TIBERG FREDRIK [SE]; JOHANSSON MARKUS [SE]; HARWIGSSON IAN [SE]; JOABSSON FREDRIK [SE]; JOHNSSON MARKUS [SE]


Patent No.: US8545872B2  Issued: 01/Oct/2013

Title: DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF A ROTIGOTINE BASE

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 13/020414   Filing Date: 03/Feb/2011

Abstract:

The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 mum, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants.

The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

Priority: DE2002161696 Applic. Date: 2002-12-30; US2004-517157 Applic. Date: 2004-12-06; WO2003EP14902 Applic. Date: 2003-12-24

Inventor: BREITENBACH ARMIN [DE]


Patent No.: US8545881B2  Issued: 01/Oct/2013

Title: Orally disintegrating tablets and methods of manufacture

Applicant/Assignee: EURAND PHARMACEUTICALS, LTD

Application No.: 10/827106   Filing Date: 19/Apr/2004

Abstract:

A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.

Priority:

Inventor: VENKATESH GOPI M [US]; QIAN KEN KANGYI [US]; VANGALA SHYAM [US]; CLEVENGER JAMES M [US]; GUENTHER DONALD [US]


Patent No.: US8545886B2  Issued: 01/Oct/2013

Title: Extended release tablet formulations of flibanserin and method for manufacturing the same

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/837957   Filing Date: 13/Aug/2007

Abstract:

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance

b) one or more pharmaceutically acceptable pH-dependent polymers

c) one or more pharmaceutically acceptable pH-independent polymers

d) one or more pharmaceutically acceptable acids

and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

Priority: EP20060118896 Applic. Date: 2006-08-14

Inventor: EISENREICH WOLFRAM [DE]; FRIEDL THOMAS [DE]


Patent No.: US8545888B2  Issued: 01/Oct/2013

Title: Tendon Stem Cells

Applicant/Assignee: THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

Application No.: 12/663663   Filing Date: 13/Jun/2008

Abstract:

The invention relates to tendon stem cell useful for treating a variety of diseases and conditions, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin.

Priority: US2007-934606P Applic. Date: 2007-06-14; WO2008US07426 Applic. Date: 2008-06-13

Inventor: YOUNG MARIAN F [US]; BI YANMING [US]; SHI SONGTAO [US]


Patent No.: US8545927B2  Issued: 01/Oct/2013

Title: LACTOFERRIN-BASED BIOMATERIALS FOR TISSUE REGENERATION AND DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF CONNECTICUT

Application No.: 13/104653   Filing Date: 10/May/2011

Abstract:

The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle.

Priority: US2010-332935P Applic. Date: 2010-05-10

Inventor: NAIR LAKSHMI SREEDHARAN [US]


Patent No.: US8546334B2  Issued: 01/Oct/2013

Title: Device having osteoinductive and osteoconductive properties

Applicant/Assignee: SCIL TECHNOLOGY GMBH

Application No.: 10/496399   Filing Date: 27/Mar/2002

Abstract:

The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation.

Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.

Priority: EP20010127573 Applic. Date: 2001-11-19; WO2002EP03463 Applic. Date: 2002-03-27

Inventor: KOHNERT ULRICH [DE]; POHLING SYLKE [DE]; HELLERBRAND KLAUS [DE]; HAPPERSBERGER PETER [DE]


Patent No.: US8551520B2  Issued: 08/Oct/2013

Title: CONTROLLED RELEASE HYDROCODONE

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 13/721293   Filing Date: 20/Dec/2012

Abstract:

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Priority: US201213535996 Applic. Date: 2012-06-28; US2010-914054 Applic. Date: 2010-10-28; US2009-378586 Applic. Date: 2009-02-17; US2003-660349 Applic. Date: 2003-09-11; US2001-016651 Applic. Date: 2001-10-30; US2000-244424P Applic. Date: 2000-10-30

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN K [US]; TONELLI ALFRED [US]


Patent No.: US8551525B2  Issued: 08/Oct/2013

Title: BONE GRAFT MATERIALS AND METHODS

Applicant/Assignee: BIOSTRUCTURES, LLC

Application No.: 12/977191   Filing Date: 23/Dec/2010

Abstract:

Compositions, materials, methods and kits for bone grafting are described. In some embodiments, a bone graft composition includes about 15% to about 20% by weight collagen, about 55% to about 70% by weight bioactive glass, and about 15% to about 30% by weight a calcium phosphate. The bioactive glass and the calcium phosphate together are about 80% to about 85% by weight of the bone graft composition. In some embodiments, a bone graft composition includes a collagen matrix and a plurality of bioactive glass particulates dispersed throughout the collagen matrix. The collagen matrix is about 20% to about 60% by weight of the bone graft composition, and the bioactive glass is about 40% to about 80% of the bone graft composition. In some embodiments, a majority of the bioactive glass particulates are about 53 mum to about 425 mum in size.

Priority:

Inventor: COOK RUSSELL L [US]; ANTONE DURAID S [US]


Patent No.: US8557262B2  Issued: 15/Oct/2013

Title: DIVINYL ETHER DERIVATIVES CAPABLE OF RELEASING ACTIVE ALDEHYDES AND KETONES AND METHODS OF USE FOR PERFUMING SURFACES

Applicant/Assignee: FIRMENICH SA

Application No.: 13/057416   Filing Date: 31/Aug/2009

Abstract:

The present invention provides divinyl ether derivatives capable of releasing in a controlled manner at least one active aldehyde and/or ketone into the surrounding environment. The invention relates to the use of these divinyl ether derivatives as perfuming or flavoring ingredients, as well as to the perfuming compositions and consumer articles containing them.

Priority: WO2008IB53695 Applic. Date: 2008-09-12; US2008-096544P Applic. Date: 2008-09-12; WO2009IB53790 Applic. Date: 2009-08-31

Inventor: WOMACK GARY BERNARD [US]; FULLER ROBERT LANGLEY [US]; VERHOVNIK GLENN PAUL JOHANNES [CH]; PINEL NATHALIE [FR]; LATEULERE MAGALI [CH]; BUY MARIE [FR]


Patent No.: US8557277B2  Issued: 15/Oct/2013

Title: MEDICAL PRODUCTS INCLUDING MODIFIED EXTRACELLULAR MATRIX MATERIALS

Applicant/Assignee: COOK BIOTECH INCORPORATED

Application No.: 12/780271   Filing Date: 14/May/2010

Abstract:

Described, in certain aspects, are medical products comprised of uniquely prepared remodelable extracellular matrix (ECM) materials retaining at least a portion of their native bioactivity. Also described are methods for forming and using such products. In one embodiment, an inventive product comprises a layer of remodelable ECM material modified through contact with periodic acid or a salt thereof. In some forms, such a modified ECM material layer includes non-native Schiff's base crosslinks within and/or between certain components of the ECM material (e.g., between two collagen molecules, two non-collagen molecules, and/or a collagen molecule and a non-collagen molecule). Other inventive products are comprised of various gels, foams, pastes, and formed, coherent, porous bodies at least containing ECM materials that have been modified in accordance with the present invention.

Priority: WO2008US86144 Applic. Date: 2008-12-10; US2007-012569P Applic. Date: 2007-12-10

Inventor: VIRKLER JOEL A [US]; NINAN LAL [US]; SHAH BHAVIN [US]


Patent No.: US8557286B1  Issued: 15/Oct/2013

Title: Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix

Applicant/Assignee: EUROCELTIQUE, S.A

Application No.: 09/980727   Filing Date: 20/Apr/2000

Abstract:

The invention relates to a method for producing pharmaceutical forms or preliminary stages thereof by means of extrusion. The pharmaceutical form has a matrix which the active agent is contained essentially, and whose essential characteristics are determined by the extrusion process and which comprises a polysaccharide and/or derivative thereof and/or a complex thereof and/or any mixture of the aforementioned substances with other substances and/or saccharides and/or derivatives thereof as an essential constituent, and at least one pharmaceutically active substance. The invention also relates to a pharmaceutical form which has a matrix in which the active agent is contained essentially, and whose essential characteristics are determined by the extrusion process, and which comprises a polysaccharide and/or derivative thereof and/or a complex thereof and/or any mixture of the aforementioned substances with other substances and/or saccharides and/or derivatives thereof as an essential constituent, and at least one pharmaceutically active substance. Finally, the invention also relates to the use of said pharmaceutical form for producing granulates for tabletting and filling capsules, for further processing using injection molding techniques and as an auxiliary material for direct tabletting and/or for producing monobloc pharmaceutical forms.

Priority: WO2000EP03612 Applic. Date: 2000-04-20; DE1999118325 Applic. Date: 1999-04-22

Inventor: REIN HUBERT [DE]; STEFFENS KLAUS-JURGEN [DE]


Patent No.: US8557287B2  Issued: 15/Oct/2013

Title: Silicone gel composition and dispenser therefor

Applicant/Assignee:

Application No.: 10/913656   Filing Date: 06/Aug/2004

Abstract:

A therapeutic silicone composition and a delivery device operable for the self-administration of the therapeutic silicone composition to the skin. Silicone gel compositions are known in the art to promote wound healing and reduce scarring. The therapeutic silicone composition of the present invention contains a silicone gel formulated with inert thickening agents and/or carriers sufficient to provide a firm, semisolid silicone gel material that substantially retains its shape when extruded from a tube. When topically applied to hypertrophic tissue, the composition, which is applied as a light film to cover the tissue, is transparent and substantially dry, obviating the need for an occlusive dressing.

Priority:

Inventor: SCHLEUNING JEFF S [US]


Patent No.: US8557288B2  Issued: 15/Oct/2013

Title: HYDROGEL MICROPARTICLE FORMATION IN AQUEOUS SOLVENT FOR BIOMEDICAL APPLICATIONS

Applicant/Assignee: WASHINGTON UNIVERSITY

Application No.: 12/540937   Filing Date: 13/Aug/2009

Abstract:

The field of the disclosure relates to microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof. Further, the field of the disclosure relates to coatings and scaffolds comprising microparticles and the processes for forming thereof.

Priority: US2008-089310P Applic. Date: 2008-08-15

Inventor: ELBERT DONALD L [US]; NICHOLS MICHAEL D [US]; SCOTT EVAN A [US]


Patent No.: US8562972B2  Issued: 22/Oct/2013

Title: Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 11/877475   Filing Date: 23/Oct/2007

Abstract:

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

Priority: US2006-853971P Applic. Date: 2006-10-23; US2006-855629P Applic. Date: 2006-10-30; US2007-997022P Applic. Date: 2007-09-28

Inventor: EDINGER JAMES W [US]; HARIRI ROBERT J [US]; WANG JIA-LUN [US]; YE QIAN [US]; LABAZZO KRISTEN S [US]; PEREIRA MARIAN [US]; ABRAMSON SASCHA DAWN [US]


Patent No.: US8563592B2  Issued: 22/Oct/2013

Title: BLADDER CANCER TREATMENT AND METHODS

Applicant/Assignee: SPECTRUM PHARMACEUTICALS, INC

Application No.: 13/083424   Filing Date: 08/Apr/2011

Abstract:

Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Priority: US2008-327781 Applic. Date: 2008-12-03; US2005-096566 Applic. Date: 2005-04-01; US2002-285783 Applic. Date: 2002-11-01; US2009-396158 Applic. Date: 2009-03-02; US2007-673537 Applic. Date: 2007-02-09; US2001-344446P Applic. Date: 2001-11-01; US2006-771678P Applic. Date: 2006-02-09

Inventor: NUIJEN BASTIAAN [NL]; PFADENHAUER ERNIE [US]; BEIJNEN JOS H [NL]; MIREJOVSKY DORLA [US]; REDDY GURU [US]; LENAZ LUIGI [US]


Patent No.: US8567410B2  Issued: 29/Oct/2013

Title: Magnet-Field Controlled Active Substance Transfer for Aerosol Therapy

Applicant/Assignee: LUDWIGS-MAXIMILIANS-UNIVERSITAET, ETHRIS GMBH

Application No.: 11/991535   Filing Date: 25/Aug/2006

Abstract:

The present invention relates to aerosols containing magnetic particles, wherein the aerosols comprise magnetic particles and a pharmaceutical active agent. The invention furthermore relates to the use of such aerosols containing magnetic particles for directed magnetic field-guided transfer of the active agents contained therein in aerosol therapy.

Priority: DE20051042768 Applic. Date: 2005-09-08; WO2006EP08357 Applic. Date: 2006-08-25

Inventor: RUDOLPH CARSTEN [DE]; ROSENECKER JOSEPH [DE]


Patent No.: US8568778B2  Issued: 29/Oct/2013

Title: MULTIPARTICULATE FORM OF ADMINISTRATION, COMPRISING NUCLEIC ACID-CONTAINING MUCOADHESIVE ACTIVE INGREDIENTS, AND METHOD FOR PRODUCING SAID FORM OF ADMINISTRATION

Applicant/Assignee: EVONIK ROEHM GMBH

Application No.: 11/721399   Filing Date: 05/Nov/2005

Abstract:

The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.

Priority: DE20041059792 Applic. Date: 2004-12-10; WO2005EP11864 Applic. Date: 2005-11-05

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; TRUPTI DAVE [DE]; GOTTSCHALK MICHAEL [DE]


Patent No.: US8568808B2  Issued: 29/Oct/2013

Title: Intercalated layered silicate

Applicant/Assignee: CRYOVAC, INC

Application No.: 11/667424   Filing Date: 02/Dec/2005

Abstract:

An intercalated layered silicate comprises a layered silicate and an intercalating agent sorbed between the silicate layers of the layered silicate. The amount of intercalating agent is effective to provide an average interlayer spacing between the silicate layers of at least about 20 AA. The intercalating agent has a formula selected from formulas I through VII described herein. The intercalated layered silicate may be exfoliated by mixing it with a matrix medium and adding sufficient energy to form a dispersed-particle composition. A packaging film, such as a food packaging film, may comprise the dispersed-particle composition.

Priority: US2004-002615 Applic. Date: 2004-12-02; WO2005US43741 Applic. Date: 2005-12-02

Inventor: GRAH MICHAEL D [US]; BECRAFT MICHAEL L [US]; SPEER DREW V [US]; BEALL GARY W [US]; BARTELS JEREMY [US]


Patent No.: US8569416B2  Issued: 29/Oct/2013

Title: SINGLE PHASE SILICONE ACRYLATE FORMULATION

Applicant/Assignee: DOW CORNING CORPORATION, DOW CORNING FRANCE SAS

Application No.: 13/278979   Filing Date: 21/Oct/2011

Abstract:

This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that is the reaction product of a silicon-containing pressure sensitive adhesive composition, a (meth)acrylate, and an initiator. A method of minimizing phase separation of the single phase silicone acrylate formulation includes the step of combining (A) and (B) to form the single phase silicone acrylate formulation.

Priority: US2008-303362 Applic. Date: 2008-12-03; WO2007US13321 Applic. Date: 2007-06-06; US2006-811246P Applic. Date: 2006-06-06

Inventor: EVANS CHANA WILSON [US]; HUBER ROBERT O [US]; KANIOS DAVID P [US]; LOUBERT GARY LEE [US]; MENJOULET TIFFANY ANNE [US]; MITCHELL TIMOTHY PAUL [US]; NARTKER LINDA SUE [US]; THOMAS XAVIER JEAN-PAUL [FR]


Patent No.: US8574606B2  Issued: 05/Nov/2013

Title: Liquid agrochemical composition containing hydrophobic agrochemical active compound

Applicant/Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED

Application No.: 12/010864   Filing Date: 30/Jan/2008

Abstract:

There is provided a liquid agrochemical composition having a stable water-diluted state, which comprises 0.5 to 30% by weight of one or more hydrophobic agrochemical active compounds, 1 to 20% by weight of one or more nonionic surfactants selected from the group consisting of a polyoxyethylene polyoxypropylene block copolymer and the like, 0 to 10% by weight of one or more anionic surfactant, 6 to 60% by weight of gamma-butyrolactone, and 20 to 75% by weight of 1,3-dimethyl-2-imidazolidinone

and water-diluted solution obtained by diluting the liquid agrochemical composition with a 10 to 10,000-fold amount of water.

Priority: JP20070021176 Applic. Date: 2007-01-31

Inventor: KOZUKI YUMIKO [JP]


Patent No.: US8574627B2  Issued: 05/Nov/2013

Title: Coated surgical mesh

Applicant/Assignee: ATRIUM MEDICAL CORPORATION

Application No.: 11/978840   Filing Date: 30/Oct/2007

Abstract:

A surgical mesh is formed of a biocompatible mesh structure with a coating that provides anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a implantation in a patient. The coating is generally formed of a fish oil, can include vitamin E, and may be at least partially cured. In addition, the coating can include a therapeutic agent component, such as a drug or other therapeutic agent.

Priority: US2006-856983P Applic. Date: 2006-11-06

Inventor: MARTAKOS PAUL [US]; HERWECK STEVE A [US]; PROWSE JOCELYN [US]; HORTON ANTHONY RICHARD [US]; FAUCHER KEITH M [US]; FERRARO JOSEPH [US]


Patent No.: US8574628B2  Issued: 05/Nov/2013

Title: NATURAL, MULTIPLE RELEASE AND RE-USE COMPOSITIONS

Applicant/Assignee: KIMBERLY-CLARK WORLDWIDE, INC

Application No.: 13/330406   Filing Date: 19/Dec/2011

Abstract:

A composition comprising a biopolymer matrix, said biopolymer matrix comprising from about 0.1% to about 40% of an essential oil, about 30% to about 95% of a biopolymer, and about 0% to about 50% of a carrier fluid wherein a limited amount of said essential oil can be released from said matrix composition when exposed to a liquid solution

and wherein an additional limited amount of said essential oil can be re-released repetitiously thereafter upon re-use with an additional exposure of a liquid solution.

Priority:

Inventor: SCHOLL NEIL T [US]; TOPOLKARAEV VASILY A [US]


Patent No.: US8575101B2  Issued: 05/Nov/2013

Title: SUPPLEMENTED MATRICES FOR THE REPAIR OF BONE FRACTURES

Applicant/Assignee: KUROS BIOSURGERY AG

Application No.: 13/167488   Filing Date: 23/Jun/2011

Abstract:

Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible, preferably biodegradable, and can be formed in vitro or in vivo, at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated in the matrix.

Priority: US2006-327214 Applic. Date: 2006-01-06; US2005-641715P Applic. Date: 2005-01-06; US2005-642644P Applic. Date: 2005-01-10

Inventor: SCHENSE JASON [CH]; WATSON JOHN [CH]; ARRIGHI ISABELLE [CH]


Patent No.: US8575223B2  Issued: 05/Nov/2013

Title: Cream for Applying on a Body

Applicant/Assignee: D & Y LABORATORIES, D&Y LABORATORIES

Application No.: 13/751796   Filing Date: 28/Jan/2013

Abstract:

A cream has at least two components, one of the components includes stable water clusters, and the cream is applied on a body to produce local surface effects, local deep effects, and non-local effects in the body.

Priority: US2009-592877 Applic. Date: 2009-12-03; US201261611981P Applic. Date: 2012-03-16

Inventor: LO SHUI YIN [US]; GANN DAVID L [US]; GANN MARTINE [US]


Patent No.: US8580248B2  Issued: 12/Nov/2013

Title: Culture and Use of Cells That Secrete Liver Secretory Factors

Applicant/Assignee: FAC8CELL PTY LIMITED

Application No.: 10/599518   Filing Date: 30/Mar/2005

Abstract:

The invention relates to an improved method of culturing hepatocyte cells and non-hepatocyte cells that are capable of secreting liver secretory factors and their use in implantable compositions for treating liver diseases and disorders in patients in need thereof.

Priority: NZ20040532057 Applic. Date: 2004-03-30; NZ20040532059 Applic. Date: 2004-03-30; NZ20040535131 Applic. Date: 2004-09-03; WO2005IB01324 Applic. Date: 2005-03-30

Inventor: ELLIOTT ROBERT BARTLETT [NZ]; GARKAVENKO OLGA [NZ]; VASCONCELLOS ALFRED [US]; EMERICH DWAINE [US]; THANOS CHRIS [US]


Patent No.: US8580830B2  Issued: 12/Nov/2013

Title: NON-MUCOADHESIVE FILM DOSAGE FORMS

Applicant/Assignee: LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH, APR APPLIED PHARMA RESEARCH S.A, LABTEC GMBH

Application No.: 12/443414   Filing Date: 02/Oct/2007

Abstract:

Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.

Priority: US2006-848965P Applic. Date: 2006-10-02; WO2007EP08579 Applic. Date: 2007-10-02

Inventor: LEICHS CHRISTIAN [DE]; BREITENBACH ARMIN [DE]; LEHRKE INGO [DE]; GALFETTI PAOLO [IT]


Patent No.: US8586007B2  Issued: 19/Nov/2013

Title: Co-polymer stabilizers for hydrofluoroalkane dispersions

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 12/738826   Filing Date: 20/Oct/2008

Abstract:

The use of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant is disclosed. The results have industrial applicability to the development of HFA-based dispersion pressurized metered-dose inhaler formulations.

Priority: US2007-981320P Applic. Date: 2007-10-19; WO2008US80547 Applic. Date: 2008-10-20

Inventor: DA ROCHA SANDRO R P [US]; WU LIBO [US]


Patent No.: US8586070B2  Issued: 19/Nov/2013

Title: Composition and device for treating bone and/or cartilage defects

Applicant/Assignee: SBF SYNTHETIC BONE FACTORY GMBH

Application No.: 13/357182   Filing Date: 24/Jan/2012

Abstract:

The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.

Priority: DE20071012276 Applic. Date: 2007-03-08; US2009-554940 Applic. Date: 2009-09-07; WO2008IB02367 Applic. Date: 2008-09-05; US2007-993146P Applic. Date: 2007-09-10

Inventor: BRIEST ARNE [DE]


Patent No.: US8586086B2  Issued: 19/Nov/2013

Title: HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS

Applicant/Assignee: POLITECNICO DI MILANO

Application No.: 12/994873   Filing Date: 29/May/2009

Abstract:

An interpenetrating biodegradable polymeric matrix hydrogel and the use thereof to support, encapsulate, convey and release several types of cells under conditions which allow the cells to be kept alive, grow and interconnect. The hydrogel may be used to prepare implants for integrally or partially regenerating, reconstructing and/or replacing damaged, dead or no longer functional tissues, in particular at the central nervous system or spinal marrow level. In such use, the biodegradability of the hydrogel allows a progressive release of the conveyed cells in order to promote their integration, even functional, with the surrounding tissue. The hydrogel may also be employed to support cells, for example, neural cells such as neuronal cells, on measuring devices, specifically realized for monitoring several parameters of cell activity, also during pharmacological and bio-mechanical tests.

Priority: IT2008MI01000 Applic. Date: 2008-05-29; IT2008MI02037 Applic. Date: 2008-11-17; WO2009IB05767 Applic. Date: 2009-05-29

Inventor: DANIELE FRANCESCO [IT]; GIORDANO CARMEN [IT]; MASI MAURIZIO [IT]; PERALE GIUSEPPE [IT]; ROSSI FILIPPO [IT]; TUNESI MARTA [IT]


Patent No.: US8586088B2  Issued: 19/Nov/2013

Title: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 13/718879   Filing Date: 18/Dec/2012

Abstract:

Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.

Priority: US201213544333 Applic. Date: 2012-07-09; US2010-909614 Applic. Date: 2010-10-21; US2003-689866 Applic. Date: 2003-10-21; US2001-781081 Applic. Date: 2001-02-08; US2000-181369P Applic. Date: 2000-02-08

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; HADDOX J DAVID [US]


Patent No.: US8586089B2  Issued: 19/Nov/2013

Title: ENHANCED CARRIERS FOR THE DELIVERY OF MICROPARTICLES TO BODILY TISSUES AND FLUIDS

Applicant/Assignee:

Application No.: 12/348290   Filing Date: 03/Jan/2009

Abstract:

Improved compositions for tissue augmentation are provided. These compositions comprise an amount of crosslinked material sufficient to provide a melt temperature (Tm) greater than 37C, wherein microparticles can be substantially uniformly dispersed and maintained at ambient room temperature as well as body temperature. Said compositions also provide high shear moduli, sufficient to effectively deliver microparticles into dense tissue and narrow intersticial spaces without significant disruption to the homogeneous distribution of microparticles within the solution. The provided compositions can be stored and shipped at room temperature without significant detriment to the material composition. Additional embodiments include a system for delivery of tissue augmentation materials and methods of manufacture thereof.

Priority:

Inventor: ANDERSON RUSSELL J [US]


Patent No.: USRE44459E1  Issued: 27/Aug/2013

Title: Method for lowering blood glucose

Applicant/Assignee: ALZA CORPORATION

Application No.: 13/410973   Filing Date: 02/Mar/2012

Abstract:

The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.

Priority: US1994-180409 Applic. Date: 1994-01-11; US2002-131916 Applic. Date: 2002-04-25; US1991-650822 Applic. Date: 1991-01-22; US1989-402314 Applic. Date: 1989-09-05

Inventor: KUCZYNSKI ANTHONY L [US]; AYER ATUL DEVDATT [US]; WONG PATRICK S L [US]


Patent No.: US8591944B2  Issued: 26/Nov/2013

Title: SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF

Applicant/Assignee: ZALICUS PHARMACEUTICALS LTD

Application No.: 13/414369   Filing Date: 07/Mar/2012

Abstract:

The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.

Priority: US201161450479P Applic. Date: 2011-03-08; US201161485405P Applic. Date: 2011-05-12

Inventor: PADVAL MAHESH V [US]; GAUTSCHI JEFF T [US]; SMITHEY DANIEL T [US]; CREW MARSHALL D [US]; HARIANAWALA ABIZER [US]


Patent No.: US8591949B2  Issued: 26/Nov/2013

Title: Aqueous Compositions Comprising A Chemical Microgel Associated With An Aqueous Polymer

Applicant/Assignee: RHODIA CHIMIE

Application No.: 12/348745   Filing Date: 05/Jan/2009

Abstract:

The invention concerns an aqueous composition comprising particles of a water-soluble or water-dispersible chemical microgel, associated with at least a water-soluble or water-dispersible crosslinking polymer, differing in composition from the particles

the amount of chemical microgel particles ranging between 0.05 to 40% by dry weight of the composition and the amount of crosslinking polymer being such that the viscosity of the composition is at least three times higher than that of an aqueous solution of chemical microgel particles and than that of an aqueous solution of crosslinking polymer, in similar conditions. The invention also concerns said composition, its use and formulations comprising same.

Priority: FR20010009387 Applic. Date: 2001-07-13; US2004-483202 Applic. Date: 2004-05-24; WO2002FR02512 Applic. Date: 2002-07-15

Inventor: BAVOUZET BRUNO [FR]; DESTARAC MATHIAS [FR]


Patent No.: US8591950B2  Issued: 26/Nov/2013

Title: HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING

Applicant/Assignee: COVIDIEN LP

Application No.: 13/115079   Filing Date: 24/May/2011

Abstract:

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Priority: US2010-348896P Applic. Date: 2010-05-27

Inventor: BENNETT STEVEN [US]; MAST NATHANIEL [US]; LAVIGNE KEVIN [US]; SKALLA WALTER [US]; SARGEANT TIMOTHY [US]; STOPEK JOSHUA [US]


Patent No.: US8592364B2  Issued: 26/Nov/2013

Title: CCR7 LIGAND DELIVERY AND CO-DELIVERY IN IMMUNOTHERAPY

Applicant/Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE ("EPFL")

Application No.: 13/025009   Filing Date: 10/Feb/2011

Abstract:

Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.

Priority: US2010-303442P Applic. Date: 2010-02-11

Inventor: SWARTZ MELODY A [CH]; HUBBELL JEFFREY A [CH]; TOMEI ALICE A [CH]; SHIELDS JACQUELINE D [GB]; KOURTIS IRAKLIS [GR]


Patent No.: US8592489B2  Issued: 26/Nov/2013

Title: STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS

Applicant/Assignee: AIR LIQUIDE SANTE (INTERNATIONAL)

Application No.: 13/097618   Filing Date: 29/Apr/2011

Abstract:

Compositions having a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R-O-CH2-CHOH-CH2OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.

Priority: DE2000128638 Applic. Date: 2000-06-09; US2005-159056 Applic. Date: 2005-06-22; US2002-297795 Applic. Date: 2002-12-09; WO2001IB00865 Applic. Date: 2001-05-17

Inventor: BEILFUSS WOLFGANG [DE]; GRADTKE RALF [DE]


Patent No.: US8597682B2  Issued: 03/Dec/2013

Title: METHOD FOR MANUFACTURING MESOPOROUS MATERIALS, MATERIALS SO PRODUCED AND USE OF MESOPOROUS MATERIALS

Applicant/Assignee: NANOLOGICA AB

Application No.: 12/867174   Filing Date: 11/Feb/2009

Abstract:

The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Priority: US2008-027538P Applic. Date: 2008-02-11; WO2009EP51575 Applic. Date: 2009-02-11

Inventor: GARCIA-BENNETT ALFONSO [SE]


Patent No.: US8597683B2  Issued: 03/Dec/2013

Title: Modified Release Tranexamic Acid Formulation

Applicant/Assignee: WATSON PHARMACEUTICALS, INC

Application No.: 12/956036   Filing Date: 30/Nov/2010

Abstract:

A modified release dosage form for the oral administration of tranexamic acid.

Priority:

Inventor: JOSHI MAYANK R [US]; FESHARAKI SHAHIN [US]


Patent No.: US8603514B2  Issued: 10/Dec/2013

Title: UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS

Applicant/Assignee: MONOSOLRX LLC, MONOSOL RX, LLC

Application No.: 11/775484   Filing Date: 10/Jul/2007

Abstract:

The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

Priority: US2004-768809 Applic. Date: 2004-01-30; WO2002US32575 Applic. Date: 2002-10-11; WO2002US32594 Applic. Date: 2002-10-11; WO2002US32542 Applic. Date: 2002-10-11; US2004-856176 Applic. Date: 2004-05-28; US2003-443741P Applic. Date: 2003-01-30; US2002-386937P Applic. Date: 2002-06-07; US2002-414276P Applic. Date: 2002-09-27; US2002-371940P Applic. Date: 2002-04-11; US2003-473902P Applic. Date: 2003-05-28

Inventor: YANG ROBERT K [US]; FUISZ RICHARD C [US]; MYERS GARRY L [US]; FUISZ JOSEPH M [US]


Patent No.: US8603526B2  Issued: 10/Dec/2013

Title: PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE

Applicant/Assignee: EGALET A/S, EGALET LTD

Application No.: 12/701429   Filing Date: 05/Feb/2010

Abstract:

The present invention provides immediate release pharmaceutical compositions for Oral administration that are resistant to abuse.

Priority: DK20090000192 Applic. Date: 2009-02-06; US2009-150620P Applic. Date: 2009-02-06

Inventor: TYGESEN PETER HOLM [DK]; OEVERGAARD JAN MARTIN [DK]; LINDHARDT KARSTEN [DK]; LYHNE-IVERSEN LOUISE INOKA [DK]; OLSEN MARTIN REX [DK]; HAAHR ANNE-METTE [DK]; HOELLUND-JENSEN JACOB AAS [DK]; HOEYRUP HEMMINGSEN PEMILLE KRISTINE [DK]


Patent No.: US8603528B2  Issued: 10/Dec/2013

Title: Compositions and method for the reduction of post-operative pain

Applicant/Assignee: ABYRX, INC

Application No.: 11/492083   Filing Date: 25/Jul/2006

Abstract:

At least three component, body-implantable, absorbable, biocompatible, putty, and non-putty pain-relieving compositions for use in surgery comprising in intimate admixture: an analgesic having local pain-relieving activity for internal relief of pain, a finely powdered bulking material, preferably less than 50 microns, e.g. the metal salts of fatty acid, hydroxyapatite, DBM, polyglycolide, polylactide, polycaprolactones, absorbable glasses, gelatin, collagens, mono, and polysaccharides starches. An organic liquid capable of solubilizing, dispensing or suspending the analgesic, such as esters of monohydric alcohols with aliphatic monocarboxylic acids

C2-C18 monohydric alcohols with polycarboxylic acids

C8-C30 monohydric alcohols

tocopherol and esters thereof with mono or polycarboxylic acids

free carboxylic acids such as oleic, capric, and lauric

dialkyl ethers and ketones

polyhydroxy compounds and esters and ethers thereof

random or block copolymers of ethylene oxide and propylene oxide.

Priority: US2004-941890 Applic. Date: 2004-09-16; US2005-702226P Applic. Date: 2005-07-25; US2006-758300P Applic. Date: 2006-01-12

Inventor: KRONENTHAL RICHARD L [US]


Patent No.: US8608661B1  Issued: 17/Dec/2013

Title: Method for intravascular delivery of a treatment agent beyond a blood vessel wall

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/792960   Filing Date: 03/Mar/2004

Abstract:

A method including positioning a delivery device at a location in a blood vessel

advancing the delivery device a distance into a wall of the blood vessel to a treatment site beyond an external elastic lamina of the blood vessel

and after advancing the delivery device, introducing a treatment agent including a cellular component through the delivery device. A composition including a treatment agent comprising a cellular component associated with a matrix material, wherein the composition is suitable for percutaneous delivery. Also an apparatus suitable for delivering a treatment agent. Also, a kit including a treatment agent.

Priority: US2001-011071 Applic. Date: 2001-11-30

Inventor: MANDRUSOV EVGENIA [US]; MICHAL EUGENE T [US]


Patent No.: US8609143B2  Issued: 17/Dec/2013

Title: Morphine polymer release system

Applicant/Assignee: EGALET A/S, EGALET LTD

Application No.: 12/078312   Filing Date: 28/Mar/2008

Abstract:

A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.

Priority: DK20010001376 Applic. Date: 2001-09-21; US2004-490169 Applic. Date: 2004-07-23; WO2002DK00619 Applic. Date: 2002-09-23

Inventor: FISCHER GINA [DK]; BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; ANDERSEN CHRISTINE [DK]


Patent No.: US8609144B2  Issued: 17/Dec/2013

Title: SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION

Applicant/Assignee: ALLERGAN, INC

Application No.: 12/142083   Filing Date: 19/Jun/2008

Abstract:

Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

Priority: US2005-118519 Applic. Date: 2005-04-29; US2004-837143 Applic. Date: 2004-04-30

Inventor: BURKE JAMES [US]; HUGHES PATRICK M [US]; WERHNER ORILLA C [US]; LIN TON C [US]; ESCOBAR MARIA [US]; HUANG GLENN [US]; ZHANG KAI-MING [US]; WHEELER LARRY A [US]; DONN ROSY S [US]


Patent No.: US8617604B2  Issued: 31/Dec/2013

Title: Pharmaceutical Compositions with Enhanced Performance

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 11/795747   Filing Date: 23/Jan/2006

Abstract:

Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.

Priority: US2005-649993P Applic. Date: 2005-02-03; US2005-649994P Applic. Date: 2005-02-03; WO2006IB00293 Applic. Date: 2006-01-23

Inventor: BABCOCK WALTER CHRISTIAN [US]; FRIESEN DWAYNE THOMAS [US]; LYON DAVID KENNETH [US]; MILLER WARREN KENYON [US]; SMITHEY DANIEL TOD [US]


Patent No.: US8617605B2  Issued: 31/Dec/2013

Title: Polymer release system

Applicant/Assignee: EGALET A/S, EGALET LTD

Application No.: 12/073692   Filing Date: 07/Mar/2008

Abstract:

A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals.

Priority: DK20010001377 Applic. Date: 2001-09-21; DK20020001044 Applic. Date: 2002-07-03; US2004-490308 Applic. Date: 2004-06-23; WO2002DK00620 Applic. Date: 2002-09-23

Inventor: FISCHER GINA [DK]; BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; LADEMANN ANNE-MARIE [DK]; ANDERSEN CHRISTINE [DK]


Patent No.: US8618157B2  Issued: 31/Dec/2013

Title: PHARMACEUTICAL FORMULATION

Applicant/Assignee: ALPHAPHARM PTY. LTD

Application No.: 13/000291   Filing Date: 04/Feb/2009

Abstract:

A pharmaceutical composition comprising: a) a 5-HT1 agonist

b) an NSAID

and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.

Priority: AU20080903115 Applic. Date: 2008-06-20; WO2009AU00132 Applic. Date: 2009-02-04

Inventor: MOONEY BRETT ANTONY [AU]; KERAMIDAS PANAGIOTIS [AU]


Patent No.: US8618175B2  Issued: 31/Dec/2013

Title: Ultrasound medical gel composition etherified hydroxyethylcellulose

Applicant/Assignee: BRUSELLS VENTURES CORP, BRUSSELS VENTURES CORP

Application No.: 13/638080   Filing Date: 18/Jul/2011

Abstract:

Ultrasound medical gel composition, the compositions comprising: (a) a gelling agent comprising etherified hydroxyethylcellulose

(b) an antimicrobial agent, specifically the quaternary ammonium compound benzalkonium chloride

(c) a solvent, 1,3-propanediol being preferred

and (d) water.

Priority: US2010-365444P Applic. Date: 2010-07-19; WO2011CA00829 Applic. Date: 2011-07-18

Inventor: HEINAR THOMAS [CA]